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Metal-dependent histone deacetylases (HDACs) catalyze the deacetylation of lysine residues in histones and
other proteins in eukaryotic cells. Isozyme HDAC8 is perhaps the archetypical member of the class I HDAC
family and serves as a paradigm for studying structure-function relationships. We report the structures of
HDAC8 complexes in a new crystal form. Comparison of unliganded and liganded structures illustrates
ligand-induced conformational changes in the L2-loop that likely accompany substrate binding and catalysis.
These structures, along with four D101 variants, support the proposal that D101 is critical for the function of
the L2 loop. Additionally, the structure of H143A HDAC8 complexed with an intact substrate confirms the
importance of D101 for substrate binding and reveals how Y306 and the active site zinc ion together bind and
activate the scissile amide linkage of acetyl-L-lysine.
The metal-dependent HDACs adopt an α/β protein fold first identified in rat liver arginase. Despite
insignificant overall amino acid sequence identity, these enzymes share a strictly conserved metal-binding site
with divergent metal specificity and stoichiometry. HDAC8, originally thought to be a Zn2+-
metallohydrolase, exhibits increased activity with Co2+ and Fe2+ based on kcat/KM (Gantt, S. L., Gattis, S.
G. & Fierke, C. A. (2006). Biochemistry 45, 6170-6178). Here, we report the first X-ray crystal structures of
metallosubstituted HDAC8: Co2+-HDAC8, D101L Co2+-HDAC8, and D101L Fe2+-HDAC8 in complex
with the inhibitor M344.
The arginase enzyme from Plasmodium falciparum contains a low complexity region insert of ~75 residues
within the L2-loop, confirming this protein region to be highly evolvable in proteins which adopt the arginase
fold. Kinetics analyses indicate this insertion to be nonessential for catalytic activity. An N-terminally tagged
construct shows KM and kcat values similar to the mammalian arginase enzymes and has been used for
crystallization. We have solved the crystal structure of the P. falciparum arginase in complex with the inhibitor
2(S)-amino-6-boronohexanoic acid, highlighting differences at the trimer interface and novel interactions
within a L8-loop insertion.
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 Abstract
Structural studies of two related metallohydrolases:
human histone deacetylase 8 and a malarial arginase
Daniel P. Dowling
Dr. David W. Christianson
Metal-dependent histone deacetylases (HDACs) catalyze the deacetylation
of lysine residues in histones and other proteins in eukaryotic cells.  Isozyme
HDAC8 is perhaps the archetypical member of the class I HDAC family and
serves as a paradigm for studying structure-function relationships.  We report
the structures of HDAC8 complexes in a new crystal form.  Comparison of
unliganded and liganded structures illustrates ligand-induced conformational
changes in the L2-loop that likely accompany substrate binding and catalysis.
These structures, along with four D101 variants, support the proposal that D101
is critical for the function of the L2 loop.  Additionally, the structure of H143A
HDAC8 complexed with an intact substrate confirms the importance of D101 for
substrate binding and reveals how Y306 and the active site zinc ion together bind
and activate the scissile amide linkage of acetyl-L-lysine.
The metal-dependent HDACs adopt an α/β protein fold first identified in
rat liver arginase.  Despite insignificant overall amino acid sequence identity,
vi
these enzymes share a strictly conserved metal-binding site with divergent metal
specificity and stoichiometry.  HDAC8, originally thought to be a Zn2+-
metallohydrolase, exhibits increased activity with Co2+ and Fe2+ based on kcat/KM
(Gantt, S. L., Gattis, S. G. & Fierke, C. A. (2006). Biochemistry 45, 6170-6178).
Here, we report the first X-ray crystal structures of metallosubstituted HDAC8:
Co2+-HDAC8, D101L Co2+-HDAC8, and D101L Fe2+-HDAC8 in complex with the
inhibitor M344.
The arginase enzyme from Plasmodium falciparum contains a low
complexity region insert of ~75 residues within the L2-loop, confirming this
protein region to be highly evolvable in proteins which adopt the arginase fold.
Kinetics analyses indicate this insertion to be nonessential for catalytic activity.
An N-terminally tagged construct shows KM and kcat values similar to the
mammalian arginase enzymes and has been used for crystallization.  We have
solved the crystal structure of the P. falciparum arginase in complex with the
inhibitor 2(S)-amino-6-boronohexanoic acid, highlighting differences at the
trimer interface and novel interactions within a L8-loop insertion.
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1 Chapter 1: Introduction
1.1 Posttranslation Protein Modification
Important biological processes are often regulated by the reversible
covalent modification of proteins involved in transcriptional regulation or
signaling pathways (Seo & Lee, 2004).  Posttranslation protein modifications alter
a protein’s chemical characteristics and include acetylation, phosphorylation,
methylation, ubiquitination, sumoylation, deimination/citrullination, proline
isomerization, and ADP-ribosylation (Seo & Lee, 2004, Kouzarides, 2007).
Specifically, the N-termini of eukaryotic histone proteins contain numerous
lysine and arginine residues which are subject to various covalent chemical
modification (Figure 1.1) (Lennartsson & Ekwall, 2009).  Coined as epigenetic
modifications (e. g. modifications involved in gene regulation without directly
altering the genetic material), histone modifications are heritable through mitosis
and meiosis (VerMilyea et al., 2009) and have crucial roles in such processes as
gene transcription, DNA repair, and gene nuclear localization (Choi & Howe,
2009, Kouzarides, 2007, Lennartsson & Ekwall, 2009, Santos-Rosa & Caldas, 2005,
Seo & Lee, 2004).  Research and intuition predict substrates for posttranslational
modification to be solvent exposed and oriented on the protein surface where
they are readily accessible to enzymes capable of catalyzing posttranslational
modifications (Pang et al., 2007).  Many of the enzymes responsible for such
modifications are able to bind specific protein sequences and catalyze reactions
with great specificity, allowing posttranslational modifications to function in fine
tuning physiological processes.
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Figure 1.1: Posttranslational modifications of histones
 Posttranslational modifications of histones H2A, H2B, H3, and H4 as identified
by mass spectroscopic techniques (Santos-Rosa & Caldas, 2005).  Large cartoon
circles represent the histone globular domain of H2A (teal), H2B (orange), H3
(lavender), and H4 (grey).  Symbol definitions: acetylation ( ); methylation ( );
phosphorylation ( ); and ubiquitination ( ).
31.2 The Nucleosome and Nucleoid
Within both prokaryotes and eukaryotes, cells must be able to compact
their entire genome within a small nucleus or nucleoid compartment.  In
humans, the genetic material is compacted within an average nuclear
compartment of approximately 10 µm diameter, while for bacteria such as E. coli
their 4.6 Mbp genome is stored within an ~0.2 µm nucleoid.  DNA must be
compacted in an organized manner to prevent DNA aggregation so that it is
usable by the cell (Sandman & Reeve, 2000).  Therefore for a human diploid cell,
6.4 million bases of DNA (approximately 2 meters in length if stretch out) must
be compacted inside the nucleus while also readily accessible for such processes
as gene transcription and DNA repair.  This compact form (i. e. chromatin)
involves tight interactions between DNA and various histone proteins (Alberts et
al., 2008, Santos-Rosa & Caldas, 2005).
The core chromatin particle (i.e. the nucleosome) consists of a histone
octamer wrapped 1.7 times around by 147 bp DNA.  Between 20-60 bp link
nucleosomes, and this “beads-on-a-string” form of DNA is further compacted by
interactions with histones H1 and H5.  The nucleosome subunit consists of two
copies of each histone dimer: H2A–H2B and H3–H4 (Figure 1.2).  These histone
proteins consist of a globular C-terminal domain and a more flexible and basic
N-terminal tail domain (Figure 1.1) (van Holde, 1989).  Histones are conserved
from yeast to humans and high levels of conservation are seen for the N-terminal
flexible tail domains.  Storage of DNA in nucleosome particles inhibits
transcription in vitro (Weihe et al., 1978) and protects segments of DNA from
4cleavage by a micrococcal nuclease (Hewish & Burgoyne, 1973, Jeong, Stein, A.,
Lohr & Van Holde, 1975).  Although transcription factor binding sites are located
primarily in nucleosome-free regions, transcription start sites generally are found
within a nucleosome (Choi & Howe, 2009).  Because of this, processes for
nucleosomal rearrangement are vital for gene expression.  The first crystal
structure of a nucleosome from Xenopus laevis shows how both the N-terminal
and C-terminal histone tails protrude from the nucleosome and are considerably
more disordered, making them ideal targets for posttranslational modifications
(Figures 1.1 and 1.2) (Luger et al., 1997).
Histone tail domains are free to make interactions with the DNA and
other nuclear proteins.  Modifications of lysine, arginine, and serine/threonine
residues (e. g. methylation, acetylation, phosphorylation, sumoylation, and
ubiquitination) at different loci within histone tails generate a “histone code”
which regulates the dynamics between hetero- and euchromatin;
heterochromatin is tightly packed and transcriptionally inactive while
euchromatin is more loosely packed and transcriptionally active (Lennartsson &
Ekwall, 2009).
In addition to studies of the eukaryotic nucleosome, great interest in how
prokaryotes package their DNA within nucleoid structures has revealed several
similarities and differences.  The prokaryotic domain Archaea is further
5Figure 1.2: Representation of the nucleosome
Surface representation of the nucleosome from Xenopus laevis consisting of ~147
bp wrapped around a histone octamer core (two of each histone H2A, H2B, H3,
and H4) (protein data bank accession code 1AOI (Luger et al., 1997)).  Molecules
are color-coded as follows: DNA (purple), H2A (teal), H2B (orange), H3 (violet),
and H4 (grey).  Black arrows designate visible N-terminal tail domains.
6subdivided into euryarchaeota, which contain histone proteins, and crenarchaeota,
which contain DNA-binding Sac proteins.  Euryarchaeota contain basic proteins
which share homology with the globular domains of eukaryotic histone proteins.
Although these proteins do not contain the basic N- or C-terminal extensions
important for higher order chromatin structures in eukaryotes, they are shown to
form hetero- and homo-tetramers capable of protecting ~70 bp from microccocal
nuclease digestion (Sandman et al., 1998, Sandman et al., 2001).  This correlates
well with data of the eukaryal H3-H4 tetramer, which similarly protects ~70 bp
from nuclease digestion (Alilat et al., 1999).  The tetrasome is a transcriptionally
active form of euchromatin, and formation of the histone octamer containing two
H2A-H2B dimers and two H3-H4 dimers locks the nucleosome together so that
additional regulation is necessary for gene transcription (e.g. posttranslational
modifications of histone-tails and nucleosome remodeling complexes) (Sandman
& Reeve, 2000).
Much less is known about the structural packaging of DNA within
bacteria.  The eukaryotic histone proteins are not conserved within bacterial
genomes; however, proteins of similar size have been discovered to interact with
prokaryote DNA.  These small proteins, considered “histone-like” proteins due
to their interactions with DNA and not sequence homology with the histone
proteins, effect DNA architecture and thus partly regulate gene transcription.
These include such examples as heat unstable protein (HU) and histone-like
nucleoid structuring factor (H-NS) (Balandina et al., 2002, Sandman et al., 1998).
7H-NS promotes DNA compaction and repression of transcription while the
addition of HU antagonizes this effect (Dorman & Deighan, 2003).
1.3 Acetylation
More than 40 years ago, Allfrey and colleagues hypothesized that gene
regulation could be achieved through the reversible acetylation of histone
proteins (Allfrey et al., 1964).  Subsequently, histone acetyl transferases and
histone deacetylases were discovered to covalently modify histone lysine
residues for gene regulation (Eberharter & Becker, 2002, Eberharter et al., 2005,
Kuo & Allis, 1998, Marmorstein, 2001, Verdone et al., 2005).  Histone acetylation
generally is associated with transcriptional activation and is found
predominantly at transcription promoters.  Acetylation of lysine residues is
thought to diminish favorable electrostatic interactions with the DNA
phosphodiester backbone, as is seen at high salt concentrations; however, at
physiological conditions histone tails interact with the nucleosome no matter the
acetylation state (Mutskov et al., 1998, Choi & Howe, 2009).  Interestingly,
acetylation of the N-terminal tails of nucleosomal histones increases their alpha-
helical content (Wang et al., 2000), indicating a change in secondary structure
upon posttranslational modification within the histone tail domains.
Considering that acetylation itself does not alter histone-DNA interactions
considerably, it is likely that protein recognition and binding of acetyl-L-lysine
within these histone tail domains plays a considerable role in gene regulation.
Since the initial discovery of the bromodomain (Figure 1.3) within the
8acetyltransferase P/CAF (Dhalluin et al., 1999), various proteins have been found
to contain the bromodomain and have increased binding affinity for acetyl-L-
lysine residues within proteins, implicating acetylation as a means to regulate
protein-protein interactions (Mujtaba et al., 2007, Dhalluin et al., 1999, Sanchez &
Zhou, 2009, Chan et al., 2009, Li & Shogren-Knaak, 2008).
The bromodomain is the only motif found thus far to preferentially bind
acetyl-L-lysine residues.  This contrasts to methyl-L-lysine binding motifs, which
include the chromodomain, PHD finger, and Tudor domains.  The structure
consists of a conserved left-handed bundle of 4 α-helices (Z, A, B, and C) and
interhelical loops ZA and BC (Figure 1.3).  The bromodomain is somewhat site-
specific, and residues within the fold are thought to make contacts with side
chains flanking the substrate acetyl-L-lysine.  While typical binding constants of
the bromodomain are in the µM - mM range, multiple bromodomain repeats
have an additive effect on protein-protein binding affinities (Sanchez & Zhou,
2009, Choi & Howe, 2009).
Genomic sequencing has revealed the presence of homologous
acetyltransferase and deacetylase genes in prokaryotes (Frye, 2000, Yang & Seto,
2008).  In archaea, the DNA-binding affinity of the protein Alba is modulated by
Sir2 deacetylation.  Such an example confirms reversible acetylation as a process
for mediating DNA-protein interactions in archaea (Wardleworth et al., 2002).
9Figure 1.3: Bromodomain
Cartoon depiction of the bromodomain from the CREB binding protein (CBP)
complexed with a H4K20ac peptide (PDB accession code 2RNY (Zeng et al.,
2008)). Y1125, Y1167, and N1168 are conserved residues engaged in acetyl-L-
lysine binding.  CBP is colored green and the H4K20ac peptide is colored yellow.
Protein atoms are colored as follows: carbon (green/yellow); oxygen (red);
nitrogen (blue).
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Reversible acetylation is documented in bacterial systems as well.  These
include a protein acetyltransferase and cobalamin biosynthetic gene product B
(Sir2 homologue) in S. enterica and the acetoin utilization A (AcuA) and AcuC
proteins in B. subtilis (Yang & Seto, 2008).  The enzyme acetyl-coenzyme A
(AcCoA) synthetase can catalyze acetylation in bacteria, transferring an acetyl
group from either acetate or AcCoA (Barak & Eisenbach, 2001).  Histone
deacetylase-like proteins (HDLPs) catalyze the deacetylation of a peptidic acetyl-
L-lysine.  An HDLP from Thermus caldophilus deacetylates histone proteins when
transfected into mammalian cells (Kim et al., 2007), suggesting a role for
reversible acetylation in bacteria.  Considering lysine deacetylase enzymes act on
myriad proteins in addition to histones, bacterial substrates most likely contain
proteins involved in cellular metabolism, including antibacterial compounds
(Wright, 1999).
1.4 Histone Deacetylase Background
The first human histone deacetylase (HDAC) was discovered by Schreiber
and colleagues using a trapoxin-based affinity resin (Taunton et al., 1996).
Designated HDAC1 and categorized as a class I HDAC, this enzyme exhibited
60% amino acid sequence identity with the yeast deacetylase RPD3.  Additional
class I enzymes characterized to date include HDAC2-3 (Yang et al., 1996,
Emiliani et al., 1998, Yang et al., 1997, Dangond et al., 1998) and HDAC8 (Buggy et
al., 2000, Hu et al., 2000, Van den Wyngaert et al., 2000).  Database mining initially
led to the discovery of class II HDAC enzymes which resemble yeast HdaI (Gray
& Ekstrom, 2001); these enzymes include HDAC4-7 (Wang et al., 1999, Miska et
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al., 1999, Grozinger et al., 1999, Fischle et al., 2001) and HDAC9-10 (Guardiola &
Yao, 2002, Kao et al., 2002, Tong et al., 2002), and contain a catalytic core of ~420
residues similar to the catalytic core of the class I enzymes (Verdin et al., 2003).
The class III enzymes are yeast Sir2 homologues, termed sirtuins, which contain
a completely different NAD-binding Rossmann fold in comparison with other
HDAC enzymes (Finnin et al., 2001, Marmorstein, 2001, Blander & Guarente,
2004).  Deacetylation by the sirtuin proteins is NAD-dependent (Imai et al., 2000,
Landry et al., 2000, Smith et al., 2000). Finally, HDAC11 is categorized as a class
IV enzyme by phylogenetic analysis (Gregoretti et al., 2004).  A summary of
mammalian histone deacetylase properties is found in Table 1.1.
Interestingly, while all enzymes in the greater HDAC family share a
common substrate, an acetylated lysine residue contained within the context of a
larger polypeptide or protein (Pang et al., 2007), the actual protein substrates and
subcellular localizations differ from one HDAC to another and several HDAC
proteins are known to deacetylate cytosolic proteins in addition to histones.  The
class I enzymes HDAC1 and HDAC2 are primarily localized in the nucleus
where they function in the nucleosome remodeling and histone deacetylation
complex (NurD) as well as the SIN3 complex, which consists of a primary core of
HDAC1, HDAC2, and the histone-binding proteins RbAp46 and RbAp48, in
addition to several other proteins containing motifs involved in chromatin-
mediated gene regulation (e.g., helicase/ATPase, chromodomain, PHD finger,
etc.) (Ahringer, 2000, Yang & Seto, 2008).  There are three co-repressors that rely
on, at least in part, the catalytic mechanisms of HDAC enzymes through
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Table 1.1: Mammalian histone deacetylase properties
Enzyme Primary localization Structural fold and metal
coordinating residues
PDB
code
HDAC interacting partnersa
Class I:
Rpd3-like HDAC1
HDAC2
HDAC3
HDAC8
Nucleus (Taunton et al., 1996)
Nucleus (Taunton et al., 1996)
Nucleus and cytoplasm2 (Yang et al., 2002)
Nucleus and cytoplasm1
Arginase/Rossmannoid
D176,H178,D264
D177,H179,D265
D170,H172,D259
D178,H180,D267
-
-
-
1T64
HDAC1,2,3 (Taplick et al., 2001)
HDAC1,3 (Taplick et al., 2001)2
HDAC1-5,73
-
Class II:
Had1-like HDAC4
HDAC5
HDAC6
HDAC7
HDAC9
HDAC10
Nucleus and cytoplasm (Grozinger & Schreiber, 2000)
Nucleus and cytoplasm (Grozinger & Schreiber, 2000)
Cytoplasm (Bertos et al., 2004)
Nucleus and cytoplasm (Lee et al., 2001)
Nucleus and cytoplasm (Zhou et al., 2001)
Nucleus and cytoplasm (Guardiola & Yao, 2002)
Arginase/Rossmannoid
D840,H842,D934
H21,C23,H34,C107b
D870,H872,D964
D649,H651,D742
D707,H709,D801
C533,C535,H541,C618b
D820,H822,D914
D172,H174,D265
2VQM
-
-
2NVR
-
-
HDAC3d,SIRT14
HDAC3d (Grozinger et al., 1999)
SIRT2,HDAC115
HDAC3 (Fischle et al., 2001)
-
-
Class III:
sirtuins,
NAD
dependent
SIRT1
SIRT2
SIRT3
SIRT4
SIRT5
SIRT6
SIRT7
Nucleus and cytoplasm6
Cytoplasm7
Mitochondria (Michishita et al., 2005)
Mitochondria (Michishita et al., 2005)
Mitochondria (Michishita et al., 2005)
Nucleus (Michishita et al., 2005)
Nucleus (Michishita et al., 2005)
Rossmannc
-
C195,C200,C221,C224
-
-
C166,C169,C207,C212
-
-
-
1J8F
-
-
2B4Y
2NYR
-
-
HDAC4 (Michan & Sinclair, 2007)
HDAC6 (North et al., 2003)
-
-
-
-
-
Class IV:
HDAC11-
related
HDAC11 Nucleus (Gao et al., 2002)
Arginase/Rossmannoid
D181,H183,D261 - HDAC6 (Gao et al., 2002, Voelter-
Mahlknecht et al., 2005)
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Table 1.1 Legend:
a  Complex partners may involve additional protein subunits in the formation of
complexes, such as RbAp46 and RbAp48 for HDAC1 and HDAC2, or C-
terminal-binding protein (CtBP), heterochromatin P1 (HP1), MEF2
transcription factor, etc., for various Class II members.
b A structural zinc is seen in the HDAC4 and HDAC7 crystal structures
(Bottomley et al., 2008, Min et al., 2007).  The HDAC4 structures show a
conformationally flexible Zn2+ binding domain.
c  In addition to a Rossmann domain, the sirtuin proteins contain a small domain
consisting of a three-stranded zinc ribbon motif (Min et al., 2001).  A
structural zinc is seen in the crystal structures of both SIRT2 (Finnin et al.,
2001) and SIRT5 (Schuetz et al., 2007, Min et al., 2006).  These residues
appear conserved throughout class III.
d  Interaction in the nucleus.
1  (Van den Wyngaert et al., 2000, Waltregny et al., 2004)
2  (Yang et al., 2002)
3   (Yang et al., 2002, Grozinger et al., 1999, Fischle et al., 2001)
4  (Grozinger et al., 1999, Michan & Sinclair, 2007)
5  (North et al., 2003, Gao et al., 2002, Voelter-Mahlknecht et al., 2005)
6  (Luo et al., 2001, Michishita et al., 2005, Vaziri et al., 2001)
7  (North et al., 2003, Onyango et al., 2002, Schwer et al., 2002, Michishita et al.,
2005)
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the interactions of NuRD, SIN3, and HDAC3, in order to functionally repress
specific gene transcription.  These co-repressors are the nuclear hormone
receptor co-repressor N-CoR, the corepressor of repressor element-1 silencing
transcription factor CoREST, and the silencing mediator of retinoic and thyroid
hormone receptors SMRT (Wen et al., 2000, Jepsen & Rosenfeld, 2002, Ahringer,
2000, Jones & Shi, 2003, Yang & Seto, 2008, You et al., 2001).  In contrast with
HDAC1 and HDAC2, HDAC3 and HDAC8 are class I enzymes found in both the
nucleus and the cytoplasm (Escaffit et al., 2007, Waltregny et al., 2004).  Class II
HDAC enzymes are subject to signal-dependent shuttling between the nucleus
and cytoplasm (Chawla et al., 2003, Grozinger & Schreiber, 2000) and also
interact with the N-CoR and/or SMRT co-repressors (Fischle et al., 2002).  The
class III enzymes (sirtuins) are nuclear, cytosolic, and mitochondrial proteins that
catalyze the deacetylation of histones and non-histone substrates such as p53 and
the FOXO transcription factor (Michishita et al., 2005).  In addition to gene
silencing, yeast Sir2 is involved in many cell functions (e.g., DNA repair and
chromosomal stability and longevity), including a role in the effects of caloric
restriction on aging (Michan & Sinclair, 2007).  Finally, the class IV enzyme
HDAC11 is localized in the nucleus where it is found in complex with HDAC6,
and its expression is tissue-specific for kidney, heart, brain, skeletal muscle, and
testis (Voelter-Mahlknecht et al., 2005, Gao et al., 2002).
Aberrant recruitment of HDAC enzymes in tumor cells (Bi & Jiang, 2006)
has increased interest in this deacetylase family as a potential pharmaceutical
target.  The inhibition of HDAC is linked to both the up-regulation and down-
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regulation of only ~2 - 5% of genes (Glaser et al., 2003, Mitsiades et al., 2004,
Moore et al., 2004, Van Lint et al., 1996).  Although the gene set transcriptionally
regulated by the HDAC inhibitors trichostatin A (TSA) and suberoylanilide
hydroxamic acid (SAHA) vary from the gene set transcriptionally regulated by
N-2-aminophenyl acylamide 3-pyridylmethyl-N-[4-[(2-aminophenyl)-carbamoyl]-
benzyl]-carbamate (MS-275), the “core” set of genes regulated by all three HDAC
inhibitors include such members as p21 (cell cycle regulation, significantly up-
regulated), TRPM-2 (apoptosis, up-regulated), thymidylate synthetase and CTP
synthase (DNA synthesis, both down-regulated), and TRP (transformation,
down-regulated).  These studies reveal HDAC-inhibited induction of p21, p27Kip1,
and/or tob1, three cell cycle regulating proteins, in p53-independent cell cycle
arrest (Glaser et al., 2003).
Treatment of pancreatic adenocarcinoma cells with TSA implicates HDAC
inhibition in signaling and transcriptional regulation, as various transcription
factor binding sites are more abundant in TSA-inhibited cells (Moore et al., 2004),
correlating with a general increase in gene transcription (Suske, 1999).  The TSA-
inhibited cells also exhibit an increased ratio of pro-apoptic BIM (a Bcl-2 family
member containing the conserved BH3-only motif (O'Connor et al., 1998)) and
anti-apoptotic Bcl-2 gene products (Moore et al., 2004), supporting the proposal
that TSA promotes apoptosis by the induction and repression of pro- and anti-
apoptosis factors, respectively.  Thus, HDAC enzymes are validated as
therapeutic drug targets for cancer chemotherapy, and several HDAC inhibitors
have entered clinical trials (Khan et al., 2008, McLaughlin & La Thangue, 2004).
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To date, Vorinostat (SAHA, marketed as Zolinza by Merck) is approved for the
treatment of cutaneous T-cell lymphoma (Duvic & Vu, 2007). Interestingly, recent
studies indicate that a potent HDAC8 inhibitor does not increase histone or
tubulin acetylation levels; yet, this inhibitor induces apoptosis in T cell-derived
tumor cells (Balasubramanian et al., 2008).
The catalytic activities of several HDAC enzymes are regulated by post-
translational modifications.  For instance, HDAC1, HDAC4 and HDAC6 are
substrates for covalent sumoylation (small ubiquitin-related modifier) which
decreases enzyme activity (Sengupta & Seto, 2004), and for HDAC1 reduces
transcriptional repression (David et al., 2002).  Covalent phosphorylation of
HDAC1 is said to decrease deacetylase activity and the ability to form complexes
(Galasinski et al., 2002, Pflum et al., 2001), although conflicting data suggest that
no change in catalytic activity results from phosphorylation (Cai et al., 2001).
While phosphorylation also activates HDAC2 and HDAC3 (Sun et al., 2002, Tsai
& Seto, 2002, Zhang et al., 2005), phosphorylation inactivates HDAC8 (Lee et al.,
2004).  This inactivation is proposed to be a result of either inhibition of acetate
product release or some alteration of the protein’s structure (Somoza et al., 2004).
Covalent phosphorylation of HDAC8 also decreases degradation of the human
ever shorter telomeres 1B protein (hEST1B/SMG5) through an unknown
mechanism, and phosphorylated HDAC8 coimmunoprecipitates with
hEST1b/SMG5.  Seto and colleagues propose that additional cofactors may be
necessary to probe the relationship between HDAC8 phosphorylation and the
ubiquitin-mediated proteasome degradation of hEST1B, since the ubiquitination
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of hEST1B is not regulated by its acetylation (Lee et al., 2006, Lee et al., 2004).
Class II HDAC enzymes are phosphorylated at two conserved serine residues
under stress conditions.  This allows HDAC4 and HDAC5 to interact with
chaperone protein 14-3-3, which shuttles these proteins to the cytoplasm
resulting in gene derepression (Grozinger & Schreiber, 2000).  This dynamic
transcriptional regulation within class II HDAC enzymes is implicated in cardiac
hypertrophy and heart failure (Zhang, McKinsey et al., 2002, Karamboulas et al.,
2006).  Further studies have identified several kinases, such as Ca2+/calmodulin-
dependent kinases and protein kinase D, which modify this class of enzymes
and/or their recognition proteins, such as the myocyte enhancer factor-2 (MEF2)
family, usually resulting in HDAC translocation to the cytoplasm (Little et al.,
2007, Ellis et al., 2003, Huynh & McKinsey, 2006, McKinsey et al., 2000).
1.5 Three-Dimensional Structures of HDAC Enzymes
The first crystal structure of a member of the HDAC family was that of a
monomeric bacterial homologue from A. aeolicus, histone deacetylase-like protein
(HDLP) (Finnin et al., 1999).  Remarkably, despite sharing only ~13% sequence
identity to arginase, HDLP was found to adopt an identical α/β fold to that of
the previously determined rat arginase I structure (Kanyo et al., 1996), consisting
of a central 8 stranded β-sheet (strand order 21387456) sandwiched between
several α-helices (Figure 1.3.1).  The subsequently determined crystal structures
of HDAC7 (Min et al., 2007) and HDAC8 (Somoza et al., 2004, Vannini et al.,
2004), as well as the crystal structure of the bacterial class IIa homologue histone
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deacetylase-like amidohydrolase (HDAH) (Nielsen et al., 2005), revealed identical
arginase topologies and monomeric structures (Figure 1.3.1); HDAC8 and
HDAH dimerize in the presence of certain inhibitors (Somoza et al., 2004,
Vannini et al., 2004, Nielsen et al., 2005).  See Chapter 5 for an in-depth analysis of
the arginase fold and structural comparison between arginase, HDAC8, and
APAH.
The structure of HDLP revealed the presence of a single metal ion
interpreted as Zn2+ at the base of a ~12 Å deep hydrophobic active site tunnel
(Finnin et al., 1999), and this arrangement was also subsequently observed in the
crystal structures of HDAC8 (Somoza et al., 2004, Vannini et al., 2004), HDAH
(Nielsen et al., 2005), and HDAC7 (Min et al., 2007) (Figure 1.3.2).  Thus, although
these enzymes share the arginase topology, indicating evolutionary divergence
from a common primordial ancestor, their metal binding specificity and
stoichiometry have substantially diverged.  Strikingly, a question still remains as
to the identity of the metal ion required for HDAC8 catalysis in vivo, since
catalytic activity is greatest with Co2+ or Fe2+ (Gantt et al., 2006).  Unpublished
work cited by Finnin and colleagues (Finnin et al., 1999) indicates comparable
activity for HDLP with Co2+ and Zn2+, but no significant activity was detected
using Fe2+ or Mn2+.
The active site metal ion is critical for the molecular recognition of
inhibitors by histone deacetylases.  Hydroxamic acid derivatives such as
trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), 4-
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(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-benzamide (M344), and 3-
(1-methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide (APHA)
(Figure 1.3.3) exhibit IC50 values in the micromolar to nanomolar range (Lin et al.,
2006).  Crystal structures of HDAC8 complexed with these compounds show that
the hydroxamic acid moiety of each inhibitor chelates the active site zinc ion
while the aliphatic linker of each inhibitor makes numerous interactions in the
active site tunnel (Figure 1.3.2) (Somoza et al., 2004, Vannini et al., 2004).  These
structural features are believed to account for the high affinity and resultant anti-
tumor effects of these inhibitors (Holbert & Marmorstein, 2005, Lin et al., 2006).
Thus, the structures of histone deacetylase-inhibitor complexes promise to
illuminate aspects of mechanism and affinity that may guide the design of
potential cancer chemotherapeutic agents.
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Figure 1.3.1: Topology diagrams of arginase and related deacetylases
Secondary structure comparison of rat arginase (Kanyo et al., 1996), HDLP
(Finnin et al., 1999), HDAC8 (Somoza et al., 2004, Vannini et al., 2004), Plasmodium
falciparum arginase (PFA), HDAC7 (Min et al., 2007), and HDAH (Nielsen et al.,
2005).  The positions of catalytic metal ions, liganded by residues at the C-
terminal ends of β-strands 4 and 7, are indicated.  The PFA L2-loop is disordered
in the crystal structure (indicated as a dashed line), and the L8-loop insertion
makes several intermonomer contacts (analyzed in Chapter 6).
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Figure 1.3.1
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Figure 1.3.2: Inhibitor binding to HDAC8
Overlay depiction of the active-site tunnel regions of histone deacetylase-like
protein (green), HDAC8 (yellow), and histone deacetylase-like amidohydrolase
(HDAH) (grey) complexed with the inhibitor suberoylanilide hydroxamic acid
(SAHA, colored green, yellow, and black for HDLP, HDAC8, and HDAH,
respectively).  The catalytic Zn2+ ion is represented as a sphere and colored
accordingly with the protein structure.  PDB accession codes 1C3S, 1T69, and
1ZZ1 (Finnin et al., 1999, Nelson et al., 2006, Somoza et al., 2004).
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Figure 1.3.3: HDAC inhibitors
Molecular structures of trichostatin A (TSA), suberoylanilide hydroxamic acid
(SAHA), 3-(1-methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide
(APHA), and 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-benzamide
(M344).
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1.6 Proposed Deacetylase Catalytic Mechanism
In HDAC8, the active site Zn2+ ion is coordinated by H180, D178, D267,
and a water molecule.  The crystal structures of the Y306F HDAC8-substrate
complex and native HDAC7 reveal a zinc-bound water molecule within
hydrogen bonding distance to both H142 and H143 (HDAC8 numbering), the
proposed general acid and general base catalytic pair (Min et al., 2007, Finnin et
al., 1999, Vannini et al., 2007, Nielsen et al., 2005, Somoza et al., 2004, Vannini et al.,
2004).  Vannini and colleagues (Vannini et al., 2007) note that the zinc-bound
water molecule is not within hydrogen bonding distance of Y306, suggesting that
this residue does not serve as a general base in the catalytic mechanism
(Kapustin et al., 2003, Vanommeslaeghe et al., 2003).  Although H142 had been
previously considered the general base in the proposed catalytic mechanism
(Finnin et al., 1999, Nielsen et al., 2005, Somoza et al., 2004, Vannini et al., 2004,
Vannini et al., 2007), recent biochemical data implicate H143 as the general base
because H143A HDAC8 is catalytically inactive (Gantt, 2006).  Weak activity
measured for H141A HDAC1 (Hassig et al., 1998) (HDAC1 H141 corresponds to
HDAC8 H143) is most likely due to copurification of other endogenous HDAC
enzymes with recombinant HDAC1 in these experiments (Hassig et al., 1998, Li et
al., 2004, Taplick et al., 2001).  Instead of serving as a general base in catalysis, the
protonated imidazolium group of H142 may play a role in stabilizing the
tetrahedral intermediate through electrostatic interactions during catalysis
(Gantt, 2006).  The C=O of the substrate acetyl moiety likely coordinates to the
Zn2+ ion and accepts a hydrogen bond from Y306, thereby polarizing the C=O
bond for nucleophilic attack by a water molecule promoted by Zn2+ and H143
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Figure 1.5: Mechanism of histone deacetylase 8
Proposed mechanism of histone deacetylase 8 (Gantt, 2006).  Classically, H142 is
suggested to be the general base and H143 the general acid (Finnin et al., 1999).
However, more recent results suggest that H143 is a general base and general
acid in the catalytic cycle as shown (Gantt, 2006).
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(Finnin et al., 1999, Min et al., 2007, Nielsen et al., 2005, Somoza et al., 2004,
Vannini et al., 2004, Vannini et al., 2007).  A mechanistic scheme consistent with
the most current structural and functional data for HDAC8 is shown in Figure
1.5.
1.7 Focus of Thesis
The structures of HDAC8 in complex with various ligands have been
solved and reveal an increase in thermal disorder within the L2-loop region of
this protein (Figure 1.3.1).  Located within this loop is a strictly conserved
aspartate which is capable of making hydrogen bonding interactions to certain
ligand functional groups, as well as accept two key hydrogen bonds from the i
and i+1 backbone NH groups surrounding a peptidic acetyl-L-lysine substrate.
Here, we use X-ray crystallography to study the structure of additional ligand
and substrate-complexes with HDAC8, as well as variants of the conserved
aspartate 101 residue.  Kinetic experiments with these variants confirms the
residue to be important for catalysis.
The HDAC enzymes discussed here are all metallohydrolases, requiring a
divalent metal ion for substrate hydrolysis.  They contain a conserved metal
binding center consisting of an Asp2His motif.  HDAC8 is active primarily with
Co2+, Fe2+, or Zn2+.  Fascinatingly, substrate affinity is metal ion-dependent.
HDAC8 metal-exchange experiments reveal varying metal-ion affinities for
different divalent metal ions.  Also, the inhibition constant of a hydroxamate
inhibitor is reported to vary with metal ion identity.  X-ray crystallographic
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studies of HDAC8 with Co2+ and Fe2+ confirm metal binding within the active
site, supporting the possibility of HDAC8 as a ferrous enzyme.
This thesis also explores the biochemistry of a Plasmodium falciparum
arginase enzyme.  Recent studies of malarial-host metabolism effects with P.
falciparum revealed the presence of a malarial arginase which is responsible for
decreased host L-arginine levels.  Considering that individuals with malaria
commonly suffer from hypoargininemia, studies of this malarial enzyme may aid
in treating this clinical effect.  The enzyme from P. falciparum (3D7 isolate) was
cloned into a vector containing a cleavable N-terminal hexahistidine tag.
Interestingly, as compared to the published C-terminally tagged construct,
activity of the N-terminally tagged construct is similar to data for human
arginase II, and thus may be more applicable for enzyme inhibition and
structural studies.  Inhibition studies revealed that the malarial enzyme is
strongly inhibited by boronic acids such as 2(S)-amino-6-boronohexanoic acid
(ABH), and this new protein construct readily forms crystals with the inhibitor
ABH.  Several structural features support the oligomeric state of this protein to
be a trimer, and novel intermonomer interactions are observed within the
malarial species based on sequence alignments.  Lastly, deletion of the ~75
residue low complexity region within the L2-loop yields an active enzyme,
confirming this external and disordered region to be uninvolved in L-arginine
hydrolysis.
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 Chapter 2: A Novel Crystal Form of HDAC8
This work is published in Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A. &
Christianson, D. W. (2008). Biochem. 47, 13554-13563.
2.1 Introduction
The X-ray crystal structure of the bacterial histone deacetylase homologue
protein from A. aeolicus (Finnin et al., 1999) revealed that this class of enzymes
adopt the same α/β fold first seen for arginase (Kanyo et al., 1996).  These
structures also revealed the presence of a divalent metal ion coordinated by three
residues (Asp2His) and gave great structural insight for hydroxamate inhibitor
binding as seen in the trichostatin A (TSA) and suberoylanilide hydroxamic acid
(SAHA) complexes.  Since then, the structures of three mammalian HDAC
enzymes (Class I HDAC8 and the catalytic domains of class IIa HDAC4 and
HDAC7) and a bacterial histone deacetylase-like amidohydrolase have been
solved (Vannini et al., 2004, Somoza et al., 2004, Bottomley et al., 2008, Schuetz et
al., 2008).
Specifically looking at HDAC8, this class I HDAC member is expected to
behave as a monomer based on solutions studies (Vannini et al., 2004).  All crystal
structures reported have either an inhibitor or substrate molecule bound in the
active site (Somoza et al., 2004, Vannini et al., 2004, Vannini et al., 2007).
Crystallization of human HDAC8 seems to be strongly dependent on the
presence of a bound ligand, and most crystallized inhibitors and substrate
molecules stabilize the formation of an artificial dimer (Figure 2.1) to promote
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crystal formation.  Until this work, the HDAC8-TSA complex published by
Somoza and colleagues was the only example of the expected monomeric form of
HDAC8 (Somoza et al., 2004).
Here, we report the X-ray crystal structures of human HDAC8 complexed
with the inhibitors TSA and 3-(1-methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-
hydroxy-2-propenamide (APHA) in a new crystal form.  Interestingly, since
APHA binds to only 2 of the 3 protein molecules in the asymmetric unit, this
structure provides insight into structural changes observed in the liganded and
unliganded forms of the enzyme.  Comparison of these structures illustrates
ligand-induced conformational changes in the L2 loop that likely accompany
substrate binding and catalysis.
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Figure 2.1: HDAC8 crystallographic dimer
Model of the artificial crystallographic dimer as seen in the HDAC8-SAHA structure
(protein data bank accession code 1T69 (Somoza et al., 2004)).  Dimerization is mediated
strongly by inhibitor binding, resulting in a buried surface area of ~1300 Å2.  Monomer A
and monomer B of the crystallographic dimer are colored green and yellow, respectively.
The inhibitor SAHA is colored as follows: carbon (light grey), nitrogen (blue), oxygen
(red).  Zn2+ ions are shown as grey spheres.
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2.2 Materials and Methods
2.2.1 Human HDAC8 plasmid construct
Plasmid for the wild type HDAC8 with a Factor Xa cleavage site and
hexahistidine tag at the carboxy terminus was kindly generated by Stephanie L.
Gantt in the laboratory of Carol A. Fierke, University of Michigan.  Briefly, the
pET-20b-derived HDAC8-His expression plasmid with optimized codon usage,
pHD2-His (Gantt et al., 2006), was modified to add a Factor Xa cleavage site
between the sequence encoding human HDAC8 and the C-terminal His6-tag,
generating the plasmid pHD2-Xa-His.  The amino acid sequence encoded by this
construct was identical to that reported by Vannini and colleagues (Vannini et al.,
2004).  Overlap extension of primers 1 and 2 was used to generate a DNA insert
containing the Stu I and Sac II restriction sites that encoded the HDAC8 sequence
from Arg353 onward, the Factor Xa cleavage site (IEGR|GS), and the His6- tag
(primer 1: 5’-GCT TTG TTA GCC GCG GGA TCT CAG TGG TGG TGG TGG
TGG TGA GAA CCA CGA CCT TCG ATA ACA ACG TGT TTC AGG TTG CCT
TTG-3’; primer 2: 5’-GCC AAG CTG CAG GCC TGA CCG CAA CGA GCC GCA
CCG CAT CCA GCA GAT CCT CAA CTA CAT CAA AGG CAA CCT GAA
ACA CGT TG-3’; restriction sites are indicated by italics and the overlapping
regions are underlined) (Gantt et al., 2006).  This insert was amplified by the
polymerase chain reaction using primers 3 and 4 (primer 3: 5’-GCC AAG CTG
CAG GCC TGA C-3’; primer 4: 5’-GCT TTG TTA GCC GCG GGA TC-3’).  Using
a QuikChange site-directed mutagenesis kit (Stratagene), a Stu I restriction site
was introduced into pHD2-His at Arg353, and a Sac II restriction site was added
five nucleotides after the stop codon following the His6-tag.  This modified
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plasmid and the DNA insert were each digested with Stu I and Sac II, and then
purified using agarose gel electrophoresis.  Finally, the insert and the plasmid
were combined using T4 DNA ligase (New England Biolabs) to generate the
plasmid pHD2-Xa-His.
2.2.2 Expression and purification of human histone deacetylase 8
Protein was expressed in E. coli BL21(DE3) cells and purified as described
(Vannini et al., 2004) with slight modifications.  Plasmid pHD2-Xa-His was
transformed into BL21(DE3) competent cells (Invitrogen) and grown up on LB-
agar plates supplemented with 100 µg/mL ampicillin at 37 °C for 12-16 hours.  A
frozen stock of BL21(DE3)pHD2-Xa-His cells was generated with 15% glycerol,
stored at –80 °C, and used for future protein expressions.  Single colonies were
used to inoculate 5 mL overnight starter cultures of LB-media supplemented
with 100 µg/mL ampicillin.  The next day, a single overnight 5 mL culture was
transferred to 250 mLs of LB-amp media and grown for 3-4 hours at 37 °C, 250
rpm.  This was used to inoculate a 5 L growth in minimal media (1X M9 salts
(Sigma), 0.4% glucose, 2 mM MgSO4, 0.1 mM CaCl2) with 100 µg/mL ampicillin.
At an OD(600 nm) of 0.5, the temperature was dropped to 18 °C.  After the
temperature stabilized, cells were induced with 0.4 mM IPTG ,100 µM ZnSO4,
and an addition 100 µg/mL ampicillin for 22 hours.  Cells were harvested at
6,000 rpm, resuspended and lysed in 50 mM Tris (pH 8.0), 5% glycerol, 0.25 %
(w/v) 1-O-n-octyl-β-D-glucopyranoside, 1 mM β-mercaptoethanol (BME), 10
µg/mL phenylmethanesulfonyl fluoride, and 1 µg/mL Nα-p-tosyl-L-arginine
methyl ester hydrochloride.  The soluble portion of the lysate was loaded onto
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nickel-nitrilotriacetic acid affinity resin (preequilibrated with 50 mM Tris (pH
8.0), 500 mM KCl, 5% glycerol, 10 mM imidazole, and 3 mM BME) and eluted
with two steps of 50 mM and 250 mM imidazole.  Protein fractions were pooled,
dialyzed into the same buffer with 10 µM ZnCl2 and no KCl, and then loaded
onto a column packed with the anion exchanger DE52 (Whatman)
(preequilibrated with 50 mM Tris (pH 8.0), 0 mM KCl, 5% glycerol, 10 mM BME).
Protein was eluted with a stepwise gradient from 0 to 500 mM KCl, and protein
fractions were then concentrated to < 5 mL and loaded onto a Superdex 26/60
column (Amersham Biosciences) preequilibrated in superdex buffer (50 mM Tris
(pH 8.0), 150 mM KCl, 5% glycerol, and 1 mM dithiothreitol) to yield > 95 % pure
protein.
2.2.3 Inhibition measurements
Activity measurements for HDAC8 variants were performed as
previously described for the wild-type enzyme (Gantt et al., 2006) using the
commercially available Fluor de Lys kit (BIOMOL) with Fluor de Lys HDAC8
substrate.  The IC50 assay mixture used to study Zn2+-HDAC8-APHA
complexation contained 50 µM fluorogenic peptide substrate, 0.5 µM HDAC8, 25
mM Tris (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1-100 µM
APHA.  Reactions were incubated at 37 degrees for 30 minutes, quenched with
stop solution (Developer II (BIOMOL) and 1 µM TSA), and tested for
deacetylated product using a fluorescence plate reader (Fluoroskan II) (ex = 355
nm, em = 460 nm).
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2.2.1 Crystallography
Zn2+-HDAC8 was used for crystallographic studies.  A new crystal form of
HDAC8 was discovered for the HDAC8-TSA and HDAC8-APHA complexes
using minor modifications of previously published conditions (Vannini et al.,
2004).  The inhibitors TSA and APHA were purchased from Sigma and used
without further purification.  Briefly, a 4 µL hanging drop of 5 mg/mL HDAC8
in 50 mM Tris (pH 8.0), 150 mM KCl, 5% glycerol, 1 mM dithiothreitol, and 2 mM
inhibitor was mixed with a 4 µL drop of precipitant buffer (0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) (pH 5.3), 1-5 % polyethylene glycol (PEG)
6000, 2 mM Tris-2-carboxyethylphosphine (TCEP)) and a 0.4 µL drop of 0.3 M
Gly-Gly-Gly, and was equilibrated against a 600 µL reservoir of precipitant
buffer at room temperature.  The final pH in the crystallization drop was 5.8.
Large plate-like crystals appeared within 1 – 5 days and grew to typical
dimensions of 300 x 150 x 50 µm3 (Figure 2.2.1).  Crystals were harvested and
cryoprotected in 25 mM Tris-HCl, 50 mM MES (pH 5.8), 75 mM KCl, 0.5 mM
TCEP, 50 µM inhibitor, and 8% or 20% polyethylene glycol (PEG) 6000 for the
APHA and TSA complexes, respectively, with 30% or 10% glycerol for the APHA
and TSA complexes, respectively.
Diffraction data were measured on beamline F1 at the Cornell High
Energy Synchrotron Source (CHESS, Ithaca, NY) for crystals of the HDAC8-TSA
complex, and beamline XL12-B at the Brookhaven National Synchrotron Light
Source (NSLS, Brookhaven, NY) for crystals of the HDAC8-APHA.  Crystal and
data collection statistics are recorded in Table 2.2.  
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Data were indexed and merged using HKL2000 (Otwinowski & Minor,
1997) and MOSFLM (Leslie, 1992).  Molecular replacement calculations were
performed with AMoRe (Navaza, 1994) using the atomic coordinates of an
inhibited form of HDAC8 less inhibitor and solvent atoms (PDB accession code
1W22) (Vannini et al., 2004) as a search probe for rotation and translation
functions for the HDAC8-TSA complex.  This refined solution was used for
molecular replacement with the HDAC8-APHA complex.  Iterative cycles of
refinement and model building were performed using CNS (Brünger, Adams,
Clore, De Lano et al., 1998) and O (Jones et al., 1991), respectively, in order to
improve each structure as guided by Rfree values.  Strict noncrystallographic
symmetry (NCS) restraints were initially used during the first few cycles of
refinement of each complex and relaxed into appropriately weighted restraints
early in refinement.  In the HDAC8-TSA and HDAC8-APHA complexes,
residues M1–Q12 at the N-termini of all monomers, residues A32-K33 of
monomer A, and residues G86-E95 of monomer C of the HDAC8-TSA complex
appeared to be disordered and were excluded from the final model.  For the
HDAC8-APHA complex, residues Q84 to E106 of monomer C appeared to be
disordered and were excluded from the final model (APHA was not observed to
bind to monomer C).  All refinement statistics are recorded in Table 2.2.
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Table 2.2: Data collection and refinement statistics
Structure Wild-type HDAC8-TSA complex
Wild-type HDAC8-
APHA complex
A. Unit cell
Space group P21 P21
Unit cell parameters
a, b, c (Å)
α, β, γ (˚)
87.9, 90.7, 92.1
90, 94.6, 90
88.4,90.4, 92.8
90, 94.7, 90
B. Data collection
Resolution limits, Å 50 - 2.54 32 – 3.3
Total/unique reflections 86,137/45,639 40,230/21,912
Completeness (%) (overall/outer shell) 96.8/97.4 98.8/99.5
Rmerge
a  (overall/outer shell) 0.097/0.508 0.136/0.435
I/σ(I)  (overall/outer shell) 11.7/2.3 8.0/3.2
No. of reflections (work set/test set) 40,864/2,177 20,014/828
B. Refinement
R/Rfreeb 0.210/0.256 0.216/0.260
Protein atomsc 8,466 8,383
Water moleculesc 102 14
Ligand atomsc 132 42d
Metal ionsc 9 9
R.m.s. deviations
Bond lengths, Å 0.007 0.008
Bond angles, ˚ 1.3 1.3
Dihedral angles, ˚ 22.0 22.0
Improper dihedral angles, ˚ 0.8 0.8
aRmerge = ∑I-〈I〉/∑I, where I is the observed intensity and 〈I〉 is the average intensity
calculated for replicate data.
bCrystallographic R factor, R = ∑(F
o 
-F
c
)/∑F
o
, for reflections contained in the
working set.  Free R factor, Rfree = ∑(Fo- Fc)/∑Fo, for reflections contained in the
test set excluded from refinement.  F
o
 and F
c
are the observed and calculated
structure factor amplitudes, respectively.
cPer asymmetric unit.
dRefined APHA occupancy = 0.7.
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Figure 2.2.1: HDAC8 monoclinic crystals
Crystals of the HDAC8-trichostatin A complex in a novel monoclinic crystal
form.  Crystal dimensions are typically 300 x 150 x 50 µm3 (unit cell parameters:
a = 87.9 Å, b = 90.7 Å, c = 92.1 Å, α = 90°, β = 94.6°, γ = 90°).
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2.2.4 Results and Discussion
Including the 3 new crystal forms described herein, a total of 9 different
crystal forms have been observed for HDAC8, its variants, and its inhibitor
complexes (Somoza et al., 2004, Vannini et al., 2004, Vannini et al., 2007).
Regardless of the crystal form, the enzyme contains a single Zn2+ ion bound in its
active site (Zn2+:protein ratio = 1:1.2 based on inductively coupled plasma
measurements); additionally, 2 K+ ions bind to structural sites identified in
earlier studies (Vannini et al., 2004, Somoza et al., 2004).  Inhibitor binding in
these complexes affects the conformations of loop segments L1 (S30 - P35) and L2
(E85 - E106) (Vannini et al., 2004, Somoza et al., 2004), which in turn appear to
affect the packing of HDAC8 monomers in the crystal lattice.  Conformational
variability of the L1 and L2 loop segments may account for the polymorphism
observed for HDAC8-inhibitor complexes.
The structures of the HDAC8-inhibitor complexes have been determined
at pH 5.8.  Given that HDAC8 exhibits a bell-shaped pH-rate profile with a low-
pH pKa of ~7, enzyme activity at pH 5.8 is low (Schultz et al., 2004).  However,
the structure of HDAC8 determined at pH 5.8 is generally identical to structures
determined at pH values of 6.8-8.0 (Somoza et al., 2004, Vannini et al., 2004,
Vannini et al., 2007), including the structure of the H143A HDAC8-substrate
complex determined at pH 8.0 discussed in Chapter 3.
Wild-Type HDAC8-Inhibitor Complexes.  The inhibitor APHA (Figure 1.3.3)
binds to HDAC8 with IC50 = 2.9 ± 0.6 µM (data not shown).  This compares with
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IC50 values of 0.1 µM and 0.5 µM measured against maize HD2 and murine
HDAC1, respectively (Mai et al., 2003), and an IC50 value of 5.9 µM for chloro-
substituted APHA against HDAC8 (Hildmann et al., 2006).  The HDAC8-APHA
complex is monomeric in the new monoclinic crystal form, and crystal packing is
such that monomers A and B form two-dimensional sheets parallel to the bc
plane, with monomer C connecting adjacent sheets (Figure 2.3.1).  A second Zn2+
binding site is observed in the L2 loop of monomer A, where the metal ion is
coordinated by H78, D87, H90, and D92 with approximate tetrahedral
coordination geometry (Figure 2.3.2).  The identity of this metal ion as Zn2+ is
confirmed in a Bijvoet difference Fourier map calculated with anomalous
scattering data (data not shown).
Only one APHA molecule binds to each of monomers A and B (Figure
2.3.3), and no inhibitor molecule binds to monomer C.  The hydroxamate moiety
of APHA does not appear to make a favorable coordination interaction with the
active site Zn2+ ion.  Although the structure is determined at 3.3 Å resolution and
is therefore subject to some ambiguity, the inhibitor molecule has limited
flexibility due to its extended π system which may impose restraints on its
binding conformation.  The best interpretation of the electron density map places
both oxygens of the hydroxamate moiety ~2.4 Å from the Zn2+ ion but poorly
oriented for metal coordination.
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Figure 2.3.1: HDAC8 monoclinic crystal packing
Packing of HDAC8 molecules in the new monoclinic crystal form.  Monomers A,
B, and C appear as pink, green, and dark blue, respectively.  The unit cell is
depicted in pink (a = 87.90 Å, b = 90.71 Å, c = 92.14 Å, β = 94.6°).
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Figure 2.3.2: Unliganded HDAC8
Superposition of unliganded monomer C (light blue) and APHA-complexed
monomer B (light green) of HDAC8 (Zn+2 is grey).  Inhibitor binding results in
the ordering of the L2 loop, which appears to be mediated by an enzyme-
inhibitor hydrogen bond with D101 (red dotted line, also illustrated in Figure
2.3.3).  A second zinc binding site is observed in the ordered L2 loop of monomer
A only.  Zn2+B (grey sphere) interacts with H78 (2.2 Å), D87 (2.6 Å), H90 (2.0 Å),
and D92 (2.6 Å).
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Figure 2.3.3: HDAC8-APHA complex inhibitor binding
Simulated-annealing omit map of APHA (magenta, contoured at 3.5σ) and Zn2+
(cyan, contoured at 11σ) in monomer B of the HDAC8-APHA complex.  α-
Helices B4 and C (which contains R167) of monomer C are shown in light blue.
The side chain of D101 in the L2 loop of monomer B accepts hydrogen bonds
from the pyrrole C=O group of APHA and R167 in helix C of monomer C.  Metal
coordination and hydrogen bond interactions are shown as solid black and
dotted red lines, respectively.
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The hydroxamate C=O group of APHA accepts a hydrogen bond from Y306, and
the hydroxamate NH and OH groups make hydrogen bond interactions with
H142, H143, and D178 (Figure 2.3.3).  Insofar as the hydroxamate C=O resembles
the carbonyl of an acetyl-L-lysine substrate, this binding mode is consistent with
the proposed role of Y306 in assisting Zn2+ with the activation of the acetyl-L-
lysine C=O group for nucleophilic attack by a metal-bound solvent molecule
promoted by H142 or H143 (Figure 1.6), as previously proposed by Somoza and
colleagues (Somoza et al., 2004).  The role of both Y306 and Zn2+ in substrate
activation is consistent with the lack of measurable catalytic activity for Y306F
HDAC8 (Vannini et al., 2007) as well as the ~7-fold variation in KM with Zn2+,
Fe2+, and Co2+ substituted HDAC8 (presuming that KM reflects enzyme-substrate
affinity in the Michaelis complex (Gantt et al., 2006)).  Notably, the presence of a
hydrogen bond donor to assist the active site Zn2+ ion in polarizing a substrate
C=O moiety was first proposed in the catalytic mechanisms of the prototypical
zinc hydrolases thermolysin (Matthews, 1988) and carboxypeptidase A
(Christianson & Lipscomb, 1989).
Apart from hydrogen bond interactions with the hydroxamate group, no
other polar interactions are observed between HDAC8 and APHA except for an
interaction between the carbonyl group adjacent to the pyrrole ring of APHA
and the side chain of D101 (Figure 2.3.3).  Presumably, D101 is protonated in
order to accommodate this interaction.
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Due to the packing arrangement of HDAC8 in the new monoclinic crystal
form (Figure 2.3.1), the active site of monomer C is unliganded and therefore
represents the first structure of unliganded HDAC8.  An electron density peak is
observed that may correspond to a non-protein Zn2+ ligand and is interpreted as
a solvent molecule.  The absence of bound inhibitor appears to be a consequence
of the fact that monomer C is much more solvent exposed, which results in
increased flexibility for loop L2 (Q84-E106) in this monomer compared with
monomers A and B.  Loop L2 is disordered in the unliganded enzyme but
becomes ordered upon the binding of APHA (Figure 2.3.2).  With APHA being a
lower affinity inhibitor in comparison with TSA, it is conceivable that the free
energy gain from HDAC8-APHA complexation is insufficient to overcome the
free energy cost of L2 loop ordering.  In monomer A, loop L2 is buttressed by
interactions with α-helices B4 and C of monomer B, and similar interactions
occur between monomers B and C (Figure 2.3.3).
Finally, the tertiary structure of the HDAC8-TSA complex resembles that
previously observed in the tetragonal crystal form (Somoza et al., 2004).  This
complex crystallizes as a monomer in the new monoclinic crystal form, in
contrast with the dimers observed in other crystal forms where the active site
loops and inhibitors themselves provide extensive surface contact (~1300 Å2)
defining a binary symmetry axis (Somoza et al., 2004, Vannini et al., 2004).  Two
molecules of TSA bind per monomer of protein, and inhibitor interactions with
the protein are identical to those previously observed in the tetragonal crystal
form (Figure 2.3.4) (18).
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Figure 2.3.4: HDAC8-trichostatin A complex inhibitor binding
Surface contour depiction of the two inhibitor binding sites in the HDAC8-
trichostatin A (TSA) complex (protein data bank accession code 3F0R).  In
general, binding of the inhibitor molecules is identical to that observed by
Somoza and colleagues (protein data bank accession code 1T64).  TSA1 and TSA2
are bound in the active site and secondary binding site, respectively, and colored
as follows: carbon (green), nitrogen (blue), oxygen (red), and the zinc ion is
colored grey.  The surface atom types are colored similarly, except that carbon is
shown in grey and sulfur in orange.
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 Chapter 3. Importance of HDAC8 L2-Loop and Residue 101
This work is published in Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A. &
Christianson, D. W. (2008). Biochem. 47, 13554-13563.
3.1 Introduction
The HDAC8-APHA complex reported in Chapter 2 reveals that residue
D101 is within hydrogen bonding distance to a carbonyl within the inhibitor’s
capping group.  This is similarly seen in other reported HDAC8 structures
(Somoza et al., 2004, Vannini et al., 2004).  D101 must be protonated to make such
a hydrogen bond.  Interestingly, Vannini and colleagues recently reported the
structure of the inactive Y306F HDAC8 variant complexed with a tetrapeptide
substrate molecule.  This structure implicates D101 in substrate binding, and it is
seen accepting two hydrogen bonds from the i and i+1 backbone NH groups
surrounding the bound acetyl-L-lysine (Vannini et al., 2007).
Here, we report the X-ray crystal structures and kinetic parameters of the
D101N, D101E, D101A, and D101L HDAC8 variants.  These structural and
kinetics studies confirm that the strictly-conserved side chain of D101 is crucial
for the function of the L2 loop.  However, amino acid substitutions for D101 can
also trigger conformational changes of Y111 and W141 that perturb the substrate
binding site.  Finally, the structure of H143A HDAC8 complexed with an intact
acetylated tetrapeptide substrate molecule further illustrates the role of D101 in
substrate binding and reveals how Y306 and the active site zinc ion together bind
and activate the amide carbonyl group of the substrate.
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3.2 Materials and Methods
3.2.1 Mutagenesis of HDAC8 residue 101
Five mutants were generated using the QuikChange mutagenesis kit
(Stratagene) with primers 1 and 2 for each respective mutant with the pHD2-Xa-
His template as follows:  D101E, primer 1: 5’-GCT AGG TTA Tga aTG CCC AGC
CAC-3’, primer 2: 5’-GTG GCT GGG CAt tcA TAA CCT AGC-3’; D101N, primer
1: 5’-GCT AGG TTA Taa cTG CCC AGC CAC-3’, primer 2: 5’-GTG GCT GGG
CAg ttA TAA CCT AGC-3’; D101L, primer 1: 5’-GCT AGG TTA Tct gTG CCC
AGC CAC-3’, primer 2: 5’-GTG GCT GGG CAc agA TAA CCT AGC-3’; D101A,
primer 1: 5’-GCT AGG TTA Tgc cTG CCC AGC CAC-3’, primer 2: 5’-GTG GCT
GGG CAg gcA TAA CCT AGC-3’; H143A, primer 1: 5’-GGT CTG GAG GGT
GGC ATg cTG CAA AGA AAG ATG AAG C-’, primer 2: 5’-GCT TCA TCT TTC
TTT GCA gcA TGC CAC CCT CCA GAC C-3’.  PCR products were transformed
into XL1-Blue cells for DNA isolation and sequencing at the University of
Pennsylvania DNA Sequencing Facility within the Abramson Cancer Center.
3.2.2 Protein expression/purification of hHDAC8 D101 variants
HDAC8 D101 variants were expressed in E. coli BL21(DE3) cells and
purified as previously described in Chapter 2, with minor modifications.  Briefly,
cells were harvested and lysed in 50 mM Tris (pH 8.0), 5% glycerol, 1 mM β-
mercaptoethanol (BME), 10 µg/mL phenylmethanesulfonyl fluoride, and 1
µg/mL Nα-p-tosyl-L-arginine methyl ester hydrochloride.  The soluble portion of
the lysate was loaded onto TALON affinity resin (Clontech) (preequilibrated
with 50 mM Tris (pH 8.0), 500 mM KCl, 5% glycerol, 10 mM imidazole, and 1
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mM BME) and eluted with two steps of 10 mM and 125 mM imidazole.  Protein
fractions were pooled, dialyzed into the same buffer with no salt, and loaded
onto a HiTrap Q HP column (GE Healthcare).  Protein was eluted with a
stepwise gradient from 0 to 500 mM KCl, and protein fractions were then
concentrated to < 5 mL and loaded onto a Superdex 26/60 column (Amersham
Biosciences) preequilibrated in Superdex buffer (50 mM Tris (pH 8.0), 150 mM
KCl, 5% glycerol, and 1 mM dithiothreitol) to yield > 95 % pure protein.
3.2.3 Generation of metal-free HDAC8 D101 variants
Divalent metal-free protein of the D101 variants was prepared as
previously described (Gantt et al., 2006).  All plasticware were presoaked in 1
mM ethylenediaminetetraacetic acid (EDTA) followed by thorough rinsing with
Milli-Q ddH2O.  All pipette tips and sample tubes were certified trace metal free
(Fisher Scientific and Corning Life Sciences).  Briefly, purified HDAC8 was
dialyzed twice into 500 mLs of (1) 25 mM MOPS (pH 7.0), 1 mM EDTA, and 10
µM dipicolinic acid, followed by buffer exchange into (2) 25 mM MOPS (pH 7.5)
and 0.1 mM EDTA, and (3) 25 mM MOPS (pH 7.5) and 1 µM EDTA.  Generated
metal-free protein was frozen and stored at -80 °C.  For Co2+-HDAC8 activity
measurements, metal-free protein was thawed and incubated on ice for an hour
with equimolar Co2+(Aldrich, 99.998% trace metals basis).
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3.2.4 Kinetics experiments
Activity measurements for HDAC8 variants were performed as
previously described for the wild-type enzyme (Gantt et al., 2006) using the
commercially available Fluor de Lys kit (BIOMOL) with Fluor de Lys HDAC8
substrate.  Because of the increased catalytic efficiency of Co2+-HDAC8 in
comparison with Zn2+-HDAC8 (Gantt et al., 2006), Co2+-substituted D101 and
H143 variants were prepared to ensure the measurement of residual catalytic
activity.  Accordingly, HDAC8 variants that were inactive with Co2+ were also
inactive with Zn2+.  Assays of catalytically active variants were performed in
triplicate or quadruplicate.
3.2.5 Crystallography
The Zn2+-HDAC8 variants were used for crystallographic studies.  The
D101 HDAC8 variants were similarly crystallized and cryoprotected as described
in Chapter 2 with slight modification of the precipitant buffer solution.
Specifically, the D101A, D101L, D101N, and D101E variants complexed with
M344 (purchased from Sigma) crystallized with 1-5% PEG 6000, PEG
monomethyl ether 550, PEG 35,000, and PEG dimethyl ether 2,000, respectively.
Crystals were cryoprotected in the same buffer with a final glycerol
concentration of 30% and 50 µM inhibitor.  The H143A variant complexed with
an acetylated tetrapeptide substrate (N-acetyl-arginine-histidine-acetyl-L-lysine-
acetyl-L-lysine-coumarin) was crystallized using a precipitant buffer of 50 mM
Tris-HCl (pH 8.0), 50 mM MgCl2, 150 mM KCl, 13% PEG 6000, 2 mM TCEP, and
3.2 mM substrate.  Crystals were subsequently transferred to a cryoprotectant
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buffer of 50 mM Tris-HCl (pH 8.0), 25 mM MgCl2, 75 mM KCl, 20% PEG 6,000, 1
mM TCEP, 20% glycerol, and 50 µM substrate as described previously for Y306F
HDAC8 (Vannini et al., 2007).
Diffraction data were measured on beamline X29 at the Brookhaven
National Synchrotron Light Source (NSLS, Brookhaven, NY) for crystals of the
D101E HDAC8 variant-M344 complex. Diffraction data for the remaining D101
HDAC8 variant-M344 complexes and the H143A HDAC8-substrate complex
were collected at beamlines ID-24C/E at the Advanced Photon Source,
Northeastern Collaborative Access Team (APS, NECAT, Argonne, Il).  Crystal
and data collection statistics are recorded in Table 3.2.
Data were indexed and merged using HKL2000 (Otwinowski & Minor,
1997) and MOSFLM (Leslie, 1992).  Molecular replacement calculations for the
D101 HDAC8 variant-M344 complexes and the H143A HDAC8-substrate
complex were performed with AMoRe (Navaza, 1994) or PHASER (McCoy et al.,
2007) using the structure of wild-type HDAC8 minus ligand and solvent atoms
as a search probe (PDB accession code 1T67) (Somoza et al., 2004).  Iterative
cycles of refinement and model building were performed using CNS (Brünger,
Adams, Clore, De Lano et al., 1998) and O (Jones et al., 1991), respectively, in
order to improve each structure as guided by Rfree values.  Strict
noncrystallographic symmetry (NCS) restraints were initially used during the
first few cycles of refinement of each complex and relaxed into appropriately
weighted restraints early in refinement.  For the HDAC8-D101 variants
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complexed with M344, disordered regions correspond to those previously
identified for the wild-type enzyme (Somoza et al., 2004).  Finally, residues M1-
S13 in all monomers of the H143A HDAC8-substrate complex are disordered and
excluded from the final model.  All refinement statistics are recorded in Table 3.2.
3.3 Results and Discussion
Interestingly, the carboxylate side chain of D101 is the only strictly-
conserved residue in the L2-loop in class I and II HDAC enzymes, and this
residue is important for substrate and inhibitor binding.  Specifically, the side
chain of D101 makes critical hydrogen bond interactions with two substrate NH
groups (Vannini et al., 2007) or the C=O , S=O, or NH groups of certain inhibitors
(Somoza et al., 2004, Vannini et al., 2004, Vannini et al., 2007), including the
pyrrole C=O group of APHA (Figure 2.3.3).  Hydrogen bond interactions
between D101 and inhibitor C=O or S=O groups require the protonated
carboxylic acid form of D101.  Recent publications of human HDAC4 and
HDAC7 crystal structures similarly confirm a key role for the corresponding
aspartate residues in their respective L2-loops (Min et al., 2007, Bottomley et al.,
2008), and these aspartate residues are also strictly conserved in histone
deacetylase-like amidohydrolases (Nielsen et al., 2005, Schafer et al., 2008).  That
D101A HDAC8 is catalytically inactive confirms that D101 is important for
substrate recognition (Vannini et al., 2007).  However, our studies now
demonstrate that D101 is functionally important not only due to its direct
interaction with ligands bound in the enzyme active site, but also due to its
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Table 3.2: Data collection and refinement statistics
Structure
D101E
HDAC8-
M344
 complex
D101A
HDAC8-
M344
complex
D101L
HDAC8-
M344
complex
D101N
HDAC8-
M344
complex
H143A
HDAC8-
substrate
complex
A. Unit cell
Space group P21 P21 P21212 P21 P212121
Unit cell parameters
a, b, c (Å)
α, β, γ (˚)
53.5, 84.7, 94.7
90, 98.1, 90
56.0, 85.9, 94.8
90, 93.7, 90
90.6, 88.9, 52.4
90, 90, 90
55.3, 85.9, 94.6
90, 93.6, 90
82.9, 91.8, 196.6
90, 90, 90
B. Data collection
Resolution limits, Å 50 - 2.85 50 - 2.55 50 -1.8 50 - 2.65 50 - 2.5
Total/unique reflections 67,864/19,641 53,446/28,356 74,694/39,760 48,874/25,531 99,678/52,790
Completeness (%) (overall/outer shell) 99.6/99.5 98.2/92.4 99.7/99.5 99.6/96.8 99.4/95.2
Rmerge
a  (overall/outer shell) 0.112/0.437 0.099/0.302 0.089/0.535 0.14/0.505 .137/.517
I/σ(I)  (overall/outer shell) 10.7/2.4 8.2/4.1 20/3.9 10.2/1.9 11.8/1.8
No. of reflections (work set/test set) 18,854/771 25,224/1,875 38,536/2,319 20,618/1,045 45,347/4,032
B. Refinement
R/Rfreeb 0.225/0.257 0.229/0.258 0.175/0.201 0.225/0.262 0.199/0.229
Protein atomsc 5,594 5,568 2,785 5,588 11,340
Water moleculesc 14 30 252 37 299
Ligand atomsc 44 44 22 44 244
Metal ionsc 6 6 3 6 14
Glycerol atomsc - - 6 - -
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Reduced BME atomsc,d 8 8 4 8 -
R.m.s. deviations
Bond lengths, Å 0.007 0.008 0.008 0.008 0.007
Bond angles, ˚ 1.3 1.3 1.4 1.3 1.3
Dihedral angles, ˚ 22.1 22.3 22.5 23.1 22.7
Improper dihedral angles, ˚ 0.8 0.8 1.0 0.9 0.8
aRmerge = ∑I-〈I〉/∑I, where I is the observed intensity and 〈I〉 is the average intensity calculated for replicate data.bCrystallographic R factor, R = ∑(F
o 
-F
c
)/∑F
o
, for reflections contained in the working set.  Free R factor, Rfree = ∑(Fo- Fc)/∑Fo,
for reflections contained in the test set excluded from refinement.  F
o
 and F
c
are the observed and calculated structure factor
amplitudes, respectively.
cPer asymmetric unit.
dRefined BME molecules with occupancies between 0.5 and 0.8.
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influence on the conformations of other active site residues important for
substrate binding, as described below.
3.3.1 Enzymology of D101 variants (A, L, N, E)
The results of activity measurements for D101A, D101L, D101N, and
D101E HDAC8 variants are recorded in Table 3.3 and are consistent with an
important role for this residue in substrate binding.  Like D101A HDAC8
(Vannini et al., 2007) (Table 3.3), D101L HDAC8 is catalytically inactive, which is
consistent with the necessity for critical enzyme-substrate hydrogen bonds
involving residue 101.  Also consistent with this expectation, the catalytic activity
of D101E HDAC8 (Figure 3.3.1) is only ~7-fold diminished compared to the wild-
type enzyme based on the value of kcat/KM, suggesting that the longer
carboxylate side chain of E101 can maintain hydrogen bond acceptor interactions
required for substrate binding.  Surprisingly, however, D101N HDAC8 exhibits
extremely low catalytic activity based on its kcat/KM and KM values.  Since only
the C=O group of the N101 side chain can accept hydrogen bonds, whereas both
the Oδ1 and Oδ2 atoms of D101 accept hydrogen bonds from the backbone NH
group of the scissile acetyl-L-lysine residue and the backbone NH group of the
adjacent residue in the n+1 position in the Y306F HDAC8-substrate complex
(Vannini et al., 2007), the catalytic inactivity of D101N HDAC8 suggests that
residue-101 must be a branched hydrogen bond acceptor capable of engaging in
two simultaneous hydrogen bond interactions with backbone NH groups of the
substrate.
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Table 3.3: Catalytic activity of D101 variants
Variant a kcat (s-1) KM (µM) kcat/KM (M-1s-1) Relative Rate b
Co2+-wild-type c 1.2 ± 0.2 160 ± 6 7500 ± 300 1.0
Zn2+-wild-type c 0.90 ± 0.03 1100 ± 50 800 ± 50 0.1
Co2+-D101E 0.15 ± 0.01 140 ± 30 1100 ± 200 0.15
Co2+-D101N n.d. d > 1000 d 0.23 ± 0.05 3 X 10-5
Co2+-D101A e n.d. d > 1000 d 0.23 ± 0.01 3 X 10-5
Co2+-D101L n.d. d > 1000 d n.d. f -
Co2+-H143A n.d. d > 1000 d 0.09 ± 0.02 1 X 10-5
a Co2+-enzyme was prepared as described in the Materials and Methods.  Co2+-
substituted HDAC8 mutants were assayed at 0.1-50 µM HDAC8 with 5-1000 µM
substrate at 25ºC in 25 mM Tris, pH 8.0, 140 mM NaCl and 2.7 mM KCl using a
minimum of 5 substrate concentrations.  Initial velocities were determined based
on changes in fluorescence.  The kinetic parameters and errors were determined
from a fit of the Michaelis-Menten equation to the resulting rates using the
program Kaleidagraph. b Value of kcat/KM (M-1s-1) relative to Co2+-wild-type
HDAC8. c Reference 23. d Activity was only detectable above 30 µM enzyme
concentrations.  At 50 µM enzyme concentrations, the value of kcat could not be
determined because the reaction rate increases linearly up to 1 mM substrate
when incubated at 25° C for 1 hour.  Thus, KM is greater than 1 mM. e Reference
25 reports inactivity; our activity measurements reveal minor residual activity. f
Catalytic efficiency could not be determined due to lack of detectable activity
using up to 10 µM enzyme and 1 mM substrate.
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Figure 3.3.1: Kinetics of residue 101 variants
(a) Michaelis-Menten kinetics of the HDAC8 E101 variant.  (b) Plot of rate
(µM/min) as a function of µM substrate concentration for the N101 and A101
variants.  Catalytic efficiency measurements were estimated assuming [S] is  <<
KM.  Assays were performed using the BIOMOL HDAC8 substrate.  Graphs were
generated using the software GraphPad Prism.
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3.3.2 Structures of D101 variants (A, L, N, E)
In order to illuminate the structural consequences of D101 amino acid
substitutions, we have determined X-ray crystal structures of each HDAC8
variant complexed with the inhibitor M344 (Figure 3.3.2), which does not require
a hydrogen bond with D101 for binding (Somoza et al., 2004).  Crystals of the
D101A, D101N, and D101E variants grow in the monoclinic space group
previously reported for wild-type HDAC8 complexed with a hydroxamate
inhibitor (Vannini et al., 2004).  Crystals of D101L HDAC8 grow in a new
orthorhombic crystal form.  Increased disorder is seen for the L2 loop in each
variant (e.g., the E85-L98 segment is completely disordered), but all D101
variants reveal clear electron density for the L2-loop flanking residue 101.
Inhibitor interactions in the D101 HDAC8 variants complexed with M344
are shown in Figure 3.3.2.  The inhibitor binding conformation is perturbed in
each variant, even though M344 does not directly interact with D101 in the wild-
type enzyme (Somoza et al., 2004).  In complexes with the D101A, D101E, and
D101N HDAC8 variants (Figure 3.3.2), the inhibitor binds with 2 alternate
conformations for the benzamide ring.  The alternate conformer is stabilized by a
hydrogen bond interaction with N101 in D101N HDAC8, but E101 is too far (~4
Å) from the inhibitor C=O in the alternate conformer to make a hydrogen bond
interaction in D101E HDAC8.
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Figure 3.3.2: Inhibitor binding in D101 variants
Binding of the inhibitor M344 to D101E, D101A, D101N, and D101L HDAC8
variants.  The two monomers of the crystallographic dimer are light green and
light blue.  Simulated annealing omit maps of inhibitor molecules and residue
101 are superimposed (contoured at 3σ, except for D101A, which is contoured at
2.5σ).  Two conformations of the bound inhibitor are observed in the active sites
of D101E, D101A and D101N HDACs (the "yellow" conformation is similar to
that observed for binding to the wild-type enzyme).  D101L HDAC8 crystallizes
in a different space group so the orientation of monomers is different from that
observed in the D101E, D101A, and D101N variants.  Electron density in the
active site of D101L HDAC8 is interpreted as a mixture of 50% bound inhibitor
and 50% two zinc-bound solvent molecules that essentially coincide with the
positions of the zinc-bound oxygen atoms of the inhibitor (inhibitors bound to
each monomer are show in yellow and green, respectively).  Zinc-bound solvent
molecules in D101L HDAC8 are show in cyan and contoured at 6σ.  Zinc and
potassium ions are grey and purple, respectively.  Zinc coordination interactions
are indicated by solid black lines and hydrogen bonds are indicated by dotted
red lines.
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Interestingly, crystal packing in the orthorhombic D101L HDAC8-M344
complex is very different from that observed in the wild-type HDAC8-M344
complex.  Electron density for the engineered leucine side chain is clear and
unambiguous (Figure 3.3.2), and linear electron density is observed between
monomer active sites such that inhibitor binding to one monomer is mutually
exclusive with inhibitor binding to its symmetry mate.  Moreover, inhibitor
occupancy is estimated to be ~50%, such that electron density is interpreted for
two zinc-bound solvent molecules with 50% occupancy that essentially coincide
with the positions of the zinc-bound oxygen atoms of the inhibitor (which does
not chelate the Zn2+ with favorable geometry).  The two zinc-bound solvent
molecules exhibit Zn2+⋅⋅⋅O separations of 2.3 Å and 2.1 Å.  One is within
hydrogen bonding distance to the Y306 hydroxyl group, while the other is within
hydrogen bonding distance to both H142 and H143.  Zinc coordination geometry
is approximately square pyramidal (Figure 3.3.3).  One zinc-bound solvent
molecule occupies the coordination site previously observed for that of the
scissile carbonyl of the substrate complexed with Y306F HDAC8 while the other
is in the same location as the zinc-bound solvent molecule in the Y306F HDAC8-
substrate complex (Vannini et al., 2007).  This is reminiscent of the catalytic Zn2+
site observed in unliganded LpxC, an unrelated bacterial deacetylase; here, too,
two solvent molecules occupy equatorial positions and a histidine residue
occupies the apical position of a square pyramidal Zn2+ coordination polyhedron
(Gennadios et al., 2006).  Presumably, the zinc coordination polyhedron in the
precatalytic Michaelis complex includes both the nucleophilic solvent molecule
and the scissile C=O of the substrate, as shown in Figure 1.6 and as revealed
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Figure 3.3.3: D101L-HDAC8 Zn2+ coordination polyhedron
Square pyramidal Zn2+ coordination polyhedron in the unliganded form of
D101L HDAC8:  D178, D267, and two solvent molecules occupy equatorial
positions, and H180 occupies the apical position (atoms are color coded as
follows:  carbon = light green, nitrogen = blue, oxygen = red, Zn2+ = grey sphere,
H2O = red spheres).  Metal coordination and hydrogen bond interactions are
shown in solid black and dotted red lines, respectively.  Superimposed are the
coordinates of the Y306F HDAC8-substrate complex (PDB accession code 2V5W)
(Vannini et al., 2007), with atoms color coded similarly except that carbon = light
blue, Zn2+ = cyan sphere, and H2O = pink sphere.  Note the correspondence of
nonprotein coordination sites on zinc.
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 in the crystal structure of Y306F HDAC8 complexed with a tetrapeptide
substrate (Vannini et al., 2007).
Unexpectedly, two additional residues, W141 and Y111, exhibit altered
conformations in the structures of D101 variants.  In the wild-type enzyme
complexed with M344, W141 and Y111 are oriented toward the active site Zn2+
ion with conformations accordingly designated as “in” (Figure 3.3.4).  The bulky
indole side chain of W141 forms one side of the pocket adjacent to Zn2+, where it
makes a van der Waals contact with the acetyl-L-lysine substrate (Vannini et al.,
2007).  The side chain of Y111 is adjacent to W141 but closer to the exterior
surface of the protein.  In the D101L HDAC8-M344 complex, both W141 and
Y111 undergo significant conformational changes such that they are oriented
away from Zn2+; these are accordingly designated “out” conformations.  A
disordered molecule of glycerol binds in the resulting void adjacent to Zn2+.  In
the D101A HDAC8-M344 complex, W141 adopts a predominantly “out”
conformation (80% occupancy) with some residual electron density indicative of
20% “in” conformation, and a BME molecule (~50% occupancy) binds in the
resulting void adjacent to Zn2+; residue Y111 is characterized by less well-defined
electron density and modeled to occupy the “in” conformation.  In the D101N
HDAC8-M344 complex, a slightly disordered W141 adopts a predominantly
“out” conformation, and a BME molecule (80% occupancy) binds in the resulting
void adjacent to Zn2+; the side chain of Y111 is disordered between the “out”
conformation (75% occupancy) and the “in” conformation (25% occupancy).  The
D101E variant exhibits similar W141 disorder, adopting 60% “out” and 40% “in”
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conformations with residual density for a BME molecule at 60% occupancy
binding similarly to that observed in the N101 and A101 variants; Y111 is
disordered with residual density for the “in” conformation.  Although the side
chain of Y111 is interpreted as disordered in previous crystal structures of
HDAC8 (Vannini et al., 2007, Somoza et al., 2004), the only previous observation
of an alternate conformation for W141 is in the HDAC8-SAHA complex (Somoza
et al., 2004).  While comparable flexibility is seen for W141 in both the wild-type
enzyme (Somoza et al., 2004) and E101 variant, even more disorder for W141 is
apparent in all catalytically inactive D101 variants.  Indeed, in the 1.8 Å
resolution structure of the D101L HDAC8-M344 complex, W141 exclusively
adopts the “out” conformation.  Thus, the catalytic inactivity of D101A, D101N,
and D101L HDAC8 variants may not only be due to the loss of important
enzyme-substrate hydrogen bonds with D101, but may also be due to alteration
of the active site contour resulting from conformational changes of W141.
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Figure 3.3.4: D101L and wild-type HDAC8-M344 complexes
Comparison of the wild-type HDAC8-M344 complex (PDB accession code 1T67,
light blue protein, purple residues and inhibitor) and the D101L HDAC8-M344
complex (light green protein, green residues and inhibitor) illustrates the “in”
and “out” conformations of the aromatic side chains of W141 and Y111.  Note
that when W141 adopts the “out” conformation, a disordered glycerol molecule
(Gol) binds in the resulting void; when Y111 adopts the “out” conformation, the
side chain of L31 moves to fill the resulting void.
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3.3.3 H143A HDAC8
The H143A substitution abolishes HDAC8 activity (Table 3.3), so this
variant was selected for cocrystallization with a bound substrate molecule.
Interestingly, some differences are apparent in substrate binding to this variant
as compared to the Y306F HDAC8-substrate complex, which crystallizes in a
different space group (Vannini et al., 2007).  In the structure of the H143A
HDAC8-substrate complex, two non-crystallographic dimers are arranged in the
asymmetric unit; the interface between these two dimers orders the tetrapeptide
substrates in monomers A and C such that their N-terminal acetyl moieties
accept hydrogen bonds from the backbone NH groups of K221 in monomers C
and A, respectively.  The substrates bound to monomers B and D are more
disordered at their N-termini.  Also, two Zn2+ ions (confirmed by anomalous
scattering) are observed to crosslink the two dimers in the asymmetric unit,
stabilizing the formation of a tetramer.  These Zn2+ ions are tetrahedrally
coordinated by two solvent molecules and a histidine and cysteine from two
different monomers: H375 of monomer A and C352 of monomer D coordinate to
ZnA2+, H375 of monomer C and C352 of monomer B coordinate to ZnB2+.
However, since the buried surface area between Zn2+-linked monomers is less
than 5% of the total surface area of each monomer, the observed tetrameric
quaternary structure is not biologically significant.
The H143A substitution does not perturb other active site residues, and
D101 accepts hydrogen bonds from the backbone NH group of acetyl-L-lysine
and the backbone NH group of the adjacent residue in the n+1 position of the
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substrate, as previously observed (Vannini et al., 2007).  Clear electron density is
observed for the carbonyl oxygen of the intact acetyl-L-lysine substrate, which
coordinates to Zn2+ (Zn2+⋅⋅⋅O separation = 1.9 Å) and accepts a hydrogen bond
from Y306 (O⋅⋅⋅O separation = 2.8 Å) (Figure 3.3.5a).  In the crystal structure of
the Y306F HDAC8-substrate complex, the deletion of the tyrosine hydroxyl
group causes the substrate acetyl moiety to shift slightly (~0.5 Å) toward F306.
Thus, the current structure is the first to show how both Zn2+ and Y306 together
can provide simultaneous electrophilic activation of the acetyl-L-lysine substrate
for nucleophilic attack.  However, no electron density is observed for an ordered
nucleophilic zinc-bound water molecule, although electron density is observed
for two water molecules bridging D183 and the side chain NH group of the
acetyl-L-lysine substrate in monomers A, B and C (Figure 3.3.5b).   This may
suggest that the interaction with H143 is important for the positioning or
activation of the catalytic water molecule in wild-type HDAC8, which is being
further investigated.
67
Figure 3.3.5: H143A-HDAC8 substrate complex
(a) Simulated annealing omit map (contoured at 2σ) showing substrate binding
to H143A HDAC8.  Metal coordination and hydrogen bond interactions are
shown as solid black and dotted red lines, respectively.  (b) Superposition of the
H143A HDAC8-substrate complex (tan) and the previously reported (Vannini et
al., 2007) Y306F HDAC8-substrate complex (light blue).  The zinc ion and water
molecules observed in the H143A HDAC8-substrate complex appear as grey and
red spheres, respectively.  The zinc ion and zinc-bound water molecule observed
in the Y306F HDAC8-substrate complex appear as cyan and pink spheres,
respectively. Metal coordination and hydrogen bond interactions are shown as
solid black and dotted red lines for the H143A HDAC8-substrate complex only.
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 Chapter 4: Metal-Substituted Histone Deacetylase
Structures
4.1 Background
While it is clear that a single transition metal ion is required for catalysis
by HDAC enzymes, the identification of the physiologically relevant metal ion
has been somewhat elusive.  The active site metal ligand set of HDAC and
HDAC-like enzymes (Asp2His) is unusual for a zinc-dependent hydrolase
(Figure 4.1).  Considering the presence of two negatively-charged aspartate
residues, which are considered “hard” metal ligands, the binding of a “hard”
metal ion is expected, e.g., such as the Mn2+ ions bound in the active site of
arginase (Kanyo et al., 1996).  Interestingly, enzymological measurements with
HDAC8 reveal that catalytic efficiency (kcat/KM) is enhanced in the presence of
Co2+ and Fe2+ in preference to Zn2+ (Gantt et al., 2006).  Notably, many
metallohydrolases are known to require a single Fe2+ ion for catalysis, including
peptide deformylase, methionyl aminopeptidase, LuxS, γ-carbonic anhydrase,
cytosine deaminase, and atrazine chlorohydrolase (Tripp et al., 2004, Seffernick et
al., 2002, Zhu et al., 2003, D'souza & Holz, 1999, Rajagopalan et al., 2000, copik et
al., 2005, Porter & Austin, 1993).  Some of these metalloenzymes were initially
misidentified as Zn2+-metallohydrolases due to the facile oxidation of Fe2+ to Fe3+,
which then dissociates and thereby allows the binding of adventitious Zn2+
(Tripp et al., 2004, Zhu et al., 2003).  It is possible that HDAC enzymes have been
similarly misidentified.
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Figure 4.1: Conserved MnB2+-site in arginase and HDLP
Depiction of the metal binding sites in rat arginase and histone deacetylase like
protein (PDB accession codes 1RLA and 1C3R, respectively).  Protein atoms are
colored grey.  Mn2+ ions and the Zn2+ ion are colored pink and dark grey,
respectively.  Hydroxide ion is shown as a red sphere.  A.) Arginase MnB2+
coordinating residues are colored green (H126), blue (D124), and orange (D234).
MnA2+ ligands are colored pale yellow (H101, D128, and D232).  B.) Conserved
MnB2+ ligands are colored similarly to arginase, and the catalytic histidine
residues are colored pale yellow.  C.) Depiction of the first catalytic step in the
proposed arginase mechanism.  D.) Depiction of the first catalytic step in the
proposed mechanism for HDAC enzymes
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Here we report the X-ray crystal structures of HDAC8 containing the
high-activity metal ions Co2+ and Fe2+ bound in the active site and coordinated by
the Asp2His ligand set.  Metal ion content is confirmed in solution by inductively
coupled plasma emission spectroscopy and in the crystal by the Bijvoet
anomalous signal from X-ray diffraction data collected at the X-ray absorption
edge of each metal ion.  These results inform the discussion regarding the
evolution of metal ion selectivity and stoichiometry in arginase and arginase-
related metalloenzymes such as HDAC.
4.2 Materials and Methods
4.2.1 Protein preparation
Recombinant HDAC8-His was prepared and purified as previously
described (Dowling, Gantt et al., 2008) and concentrated to 2-12 mg/mL for metal
exchange dialysis.  To prevent trace metal contamination, all plasticware was
presoaked with 1 mM ethylenediaminetetraacetic acid (EDTA) and triple rinsed
with Millipure H2O; glassware was not used in these experiments.  Any plastic
disposables, including pipet tips and micro-centrifuge tubes, were certified trace
metal free.  Sodium hydroxide (Sigma, 99.999%) was used to titrate 3-(N-
morpholino)propanesulfonic acid (MOPS) buffer (Ambion).  Dialysis cassettes
(Pierce) and syringes with needles were presoaked with 1 mM EDTA and
extensively washed with Millipure H2O.  When necessary, anaerobic conditions
were achieved utilizing the captair® pyramid glove bag filled with argon or
nitrogen.
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Metal-free HDAC8 was generated by dialyzing purified HDAC8 twice
into 500 mL of (1) 25 mM MOPS (pH 7.0), 1 mM EDTA, and 10 µM dipicolinic
acid, followed by buffer exchange into (2) 25 mM MOPS (pH 7.5) and 0.1 mM
EDTA, and (3) 25 mM MOPS (pH 7.5) and 1 µM EDTA.  Crystallization buffer (50
mM Tris (pH 8.0), 150 mM KCl, 5% glycerol, and 1 mM tris(2-
carboxyethl)phosphine (TCEP)) was pre-treated with chelex resin (Sigma) and
used for the final dialysis.  To prepare each metal-substituted enzyme, the metal-
free enzyme was dialyzed into crystallization buffer supplemented with 100 µM
of either CoCl2, FeCl2, MnCl2, CuCl2 (Sigma, 99.999%), NiCl2, or FeCl3 (Hampton
Research, >98%) followed by a final dialysis into crystallization buffer pre-
treated with chelex resin to remove any excess unbound divalent metal ions.
Metal content was quantified by inductively coupled plasma atomic emission
spectroscopy using a facility in the Geology Department at the University of
Michigan.
4.2.2 Metal dependent inhibition
The concentration of metal-free HDAC8 was determined using Ellman’s
Reagent as previously described (Gantt et al., 2006).  Enzyme was incubated with
equimolar CoCl2, FeCl2, or ZnCl2 on ice for 1 h, and metallosubstituted HDAC8
(0.5 µM) was assayed with 50 µM Fluor de Lys HDAC8 substrate (BIOMOL) at
25 °C in 25 mM Tris (pH 8.0), 140 mM NaCl, and 2.7 mM KCl pretreated with
chelex resin.  Fe2+-HDAC8 activity was measured in the presence of 5 mM
sodium dithionite; these conditions have no effect on enzyme activity when
tested with Zn2+-HDAC8.  Assay points were stopped with Developer II solution
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(BIOMOL) and 10 µM trichostatin A.  Inhibition constants (Ki) were calculated
for a minimum of 12 inhibitor concentrations using the Cheng-Prusoff equation
(Cheng & Prusoff, 1973).
4.2.3 Protein crystallization
Considering that HDAC8 does not readily crystallize without a bound
ligand, complexes with the inhibitor 4-(dimethylamino)-N-[7-(hydroxyamino)-7-
oxoheptyl]-benzamide (designated “M344”) were prepared to obtain diffraction
quality crystals.  The inhibitor M344 was purchased from Sigma and used
without further purification for cocrystallization experiments (2 mM).  Since
D101L HDAC8 generally yielded better quality crystals that diffracted to higher
resolution, both wild-type and mutant enzymes were used for crystallographic
studies.  For crystallization of Co2+-HDAC8, a 4 µL sitting drop of 5 mg/mL Co2+-
HDAC8-M344 complex was mixed with a 4 µL drop of precipitant buffer (0.1 M
2-(N-morpholino)-ethanesulfonic acid (MES) (pH 5.3), 0-5% polyethylene glycol
(PEG) monomethylether (MME) 550, 2 mM (TCEP), and 0.03 mM Gly-Gly-Gly,
pretreated with chelex resin) and equilibrated against a 600 µL reservoir of
precipitant buffer at room temperature.  Crystals formed after 3 - 4 weeks and
were harvested and cryoprotected in 25 mM Tris-HCl, 50 mM MES (pH 5.8), 75
mM KCl, 0.5 mM TCEP, 50 µM M344, 10 % PEG MME 550, and 30% glycerol.
For crystallization of Fe2+-HDAC8, a 4 µL sitting drop of 5 mg/mL Fe2+-
HDAC8-M344 complex was mixed with a 4 µL drop of precipitant buffer (0.1 M
MES (pH 6.8), 10-18% PEG 35K, 2 mM TCEP, and 0.03 M Gly-Gly-Gly, pretreated
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with chelex resin) and equilibrated against a 600 µL reservoir of precipitant
buffer at room temperature.  Sodium dithionite was added to the reservoir before
sealing with crystallization tape, and trays were stored under a nitrogen
atmosphere using either the captair® pyramid glove bag or a dessicator equipped
with a vacuum and gas port.  Wild-type Fe2+-HDAC8 complexed with M344
formed plate-like crystals within 1-2 days that were unsuitable for X-ray data
collection.  However, crystals of the D101L Fe2+-HDAC8-M344 complex were
larger and more suitable for X-ray data collection.  Crystals were harvested and
cryoprotected in 25 mM Tris-HCl, 50 mM MES (pH 6.8), 75 mM KCl, 0.5 mM
TCEP, 50 µM M344, 20% PEG 2,000, and 20% glycerol.
4.2.4 Data collection and structure determination
Diffraction data were measured on beamline ID-24C at the Advanced
Photon Source, Northeastern Collaborative Access Team (APS, NECAT,
Argonne, IL).  Data for the D101L HDAC8 structures were collected at 11.566
keV/1.0720 Å and either 7.725 keV/1.6050 Å or 7.120 keV/1.7143 Å for Co2+ or
Fe2+ derivatives, respectively.  Crystallographic and data collection statistics are
recorded in Tables 4.1 and 4.2.  Data were indexed and merged using HKL2000
(Otwinowski & Minor, 1997).  Molecular replacement calculations were
performed with PHASER (McCoy et al., 2007) using the structure of either wild-
type or D101L HDAC8 (PDB accession codes 1W22 or 3EW8, respectively) minus
ligands and solvent atoms as a search probe.  Iterative cycles of refinement were
performed using CNS (Brünger, Adams, Clore, Delano et al., 1998) or REFMAC
(Murshudov et al., 1997)
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Table 4.1: Data collection and refinement statistics
Structure
Wild-type
Co2+ HDAC8-
M344 complex
D101L Co2+
HDAC8-
M344
complex
D101L Fe2+
HDAC8-M344
complex
Resolution limits, Å 50 – 3.2 50 – 1.9 50 – 2.0
Energy/wavelength
(eV/Å) 7725/1.6050 11,566/1.0720 11,566/1.0720
Space Group P21 P21212 P21212
Total/unique
reflections 28,240/14,687 59,365/31,754 53,795/28,881
Completeness (%)
(overall/outer shell) 98.3/90.9 92.5/89.2 98.7/90.5
Rmerge
a
(overall/outer shell) 0.132/0.441 0.049/0.567 0.064/0.254
I/σ(I)
(overall/outer shell) 9.9/2.3 40.0/2.5 28.1/5.2
No. of reflections
(work set/test set) 12,996/684 30,130/1,602 27,382/1,457
R/Rfreeb 0.205/0.255 0.205/0.238 0.203/0.250
R.m.s. deviations
Bond lengths, Å 0.007 0.017 0.017
Bond angles, ˚ 1.2 1.5 1.5
aRmerge = ∑I-〈I〉/∑I, where I is the observed intensity and 〈I〉 is the average intensity
calculated for replicate data.
bCrystallographic R factor, R = ∑F
o 
-F
c
/∑F
o
, for reflections contained in the
working set.  Free R factor, Rfree = ∑Fo- Fc/∑Fo, for reflections contained
in the test set excluded from refinement.  F
o
 and F
c
are the observed and
calculated structure factor amplitudes, respectively.   
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Table 4.2: Anomalous scattering data collection statistics
Structure D101L Co
2+  HDAC8-
M344 complex
D101L Fe2+  HDAC8-
M344 complex
Resolution limits, Å 50 – 2.7 50 – 3.0
Energy/wavelength
(eV/Å) 7725/1.6050 7120/1.7143
Space Group P21212 P21212
Total/unique
reflections 21,310/11,556 19,561/10,633
Completeness (%)
(overall/outer shell) 99.9/100.0 98.5/89.1
Redundancy
(overall/outer shell) 8.4/8.3 8.2/4.8
Rmerge
a
(overall/outer shell) 0.162/0.567 0.129/0.230
I/σ(I)
(overall/outer shell) 13.0/5.2 15.7/4.8
aRmerge = ∑I-〈I〉/∑I, where I is the observed intensity and 〈I〉 is the average intensity
calculated for replicate data.
bCrystallographic R factor, R = ∑F
o 
-F
c
/∑F
o
, for reflections contained in the
working set.  Free R factor, Rfree = ∑Fo- Fc/∑Fo, for reflections contained
in the test set excluded from refinement.  F
o
 and F
c
are the observed and
calculated structure factor amplitudes, respectively.
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for wild type or D101L HDAC8, respectively, and models were fit into electron
density maps using COOT (Emsley & Cowtan, 2004).  At the conclusion of
refinement, residues M1-S13 at the N-terminus and residues E85-S93 appeared to
be disordered in all monomers and were excluded from each final model.  Data
collection and refinement statistics are recorded in Table 4.1.
4.3 Results
Essentially complete metal ion substitution of HDAC8 with Co2+, Fe2+,
Mn2+, or Cu2+ is confirmed by the ICP atomic emission spectroscopy data
recorded in Table 4.3.  As initially prepared, the recombinant enzyme purified in
the presence of 100 µM ZnCl2 contains Zn2+exclusively, confirming that Zn2+ is
bound in the active sites of HDAC8 structures published to date (Dowling, Gantt
et al., 2008, Somoza et al., 2004, Vannini et al., 2004, Vannini et al., 2007).  The
HDAC8 enzymes dialyzed with Co2+ or Fe2+ show full or nearly full
incorporation of the respective metal ion.  The wild-type enzyme also fully
incorporates Mn2+ and Cu2+.  HDAC8 shows no significant incorporation of Fe3+
or Ni2+ under the conditions tested.
HDAC8 inhibition by the hydroxamate M344 was tested.  The inhibition
constant (Ki) is metal ion-dependent, and inhibition data are represented in Table
4.4.  The inhibitory potency of M344 against metal-substituted HDAC8 enzymes
increases in the order Zn2+-HDAC8 < Fe2+-HDAC8 < Co2+-HDAC8.  A
comparable metal-dependent affinity trend was previously reported for the
inhibitor SAHA (Gantt et al., 2006).
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Table 4.3: Metal ion content of metallosubstituted HDAC8
Metal ion content (µM)B Metal:subunit ratioC
Fe Co Ni Cu Zn Mn Fe Co Ni Cu Zn Mn
Native HDAC8A 6.6 0.33 0.24 15.2 100 - 0.06 ND ND 0.13 0.87 -
Co2+-HDAC8 2.0 202 0.15 1.1 1.9 - 0.02 1.1 ND 0.01 0.02 -
Fe2+-HDAC8 175 16.9 0.48 17.7 12.0 - 0.79 0.08 ND 0.08 0.05 -
Fe2+-D101L HDAC8 359 <0.16 1.1 17.7 12 - 1.4 ND ND 0.07 0.05 -
Fe3+-HDAC8 3.57 18.07 0.23 4.18 5.91 0.04 0.06 0.32 ND 0.07 0.11 ND
Fe3+-D101L HDAC8 0.37 <0.04 <0.07 2.58 3.8 ND ND ND ND 0.06 0.08 ND
Fe3+-H143A HDAC8 2.18 8.53 0.22 2.05 16.9 0.13 ND 0.03 ND ND 0.07 ND
Mn2+-HDAC8 0.47 0.05 0.33 1.22 5.0 22.2 0.02 ND 0.02 0.06 0.25 1.1
Cu2+-HDAC8 0.47 0.12 0.08 48.1 6.2 ND 0.01 ND ND 1.09 0.14 ND
Ni2+-HDAC8 0.56 2.46 15.4 8.74 14.65 0.06 ND 0.02 0.14 0.08 0.13 ND
A Native HDAC8 refers to recombinant protein expressed in E. coli with 100 µM ZnCl2.
B Metallosubstituted HDAC8 was generated as described in the Materials and Methods.
Metal-free enzyme was generated by means of EDTA dialysis.  Each metal ion was
subsequently introduced at a concentration of 100 µM chloride salt and dialyzed to a
final concentration of 100 nM.  Element analysis of final protein samples was determined
by means of ICP emission spectroscopy.
C The ratios of metal ion to protein subunit was determined by means of the metal ion
concentration as determined by ICP atomic emission spectroscopy and protein
concentration as determined by Bradford assay.
D ND signifies a value of less than 0.01.
E “-“ signifies data not reported.
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Table 4.4: Metal ion dependent HDAC8 inhibition
Ki (nM)Inhibitor Co2+ Fe2+ Zn2+
H
N
H
N
OH
OO
N
M344
14.8 ± 0.8 63 ± 2 68 ± 6
N
H
H
N
OH
O
O
SAHA
44 ± 151 130 ± 401 250 ± 251
1 From: (Gantt et al., 2006).
To confirm metal binding in the crystal structure, X-ray diffraction data
for wild type and D101L HDAC8 were collected at incident wavelengths
corresponding to the absorption edges of cobalt and iron.  A strong peak in the
Bijvoet difference Fourier map of the active site in each structure corresponds to
a metal ion coordinated by D178, H180, and D267 (Figures 4.3.1 and 4.3.2).
Considering that the absorption edges of cobalt and iron (7.7089 keV and 7.1120
keV, respectively) are significantly lower than that of zinc (9.6586 keV), the
observation of these peaks in the Bijvoet difference Fourier maps confirms the
binding of Co2+ and Fe2+ in these respective crystal structures.  These
crystallographic results are consistent with the metal ion content of these protein
samples in solution (Table 4.3).  Refined metal ion coordination distances in the
Co2+ and Fe2+-substituted enzymes are comparable to those observed in Zn2+-
HDAC8 (Table 4.5).
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Table 4.5: Metal ion coordination distances (Å) in D101L HDAC8
Catalytic
Metal
Ion
M2+ –
Asp178
M2+ –
Asp267
M2+ –
His180
Catalytic
Water
Non-Catalytic
Water
Hydroxamate
(N–O; C=O)
Co2+ 2.0 2.0 2.1 1.9 2.2 2.0, 2.5
Fe2+ 1.9 2.0 2.1 1.9 2.2 2.0, 2.6
Zn2+, a 2.0 2.0 2.1 2.3 2.1 2.5, 2.3
a Data in Chapter 3.
Strong peaks in the Bijvoet difference Fourier map are also observed at the
sites corresponding to two previously reported monovalent cation binding sites
(Figure 4.3.3) (Finnin et al., 1999, Somoza et al., 2004, Vannini et al., 2004).  Metal
coordination distances average ~2.8-2.9 Å and are consistent with the binding of
K+ ions (absorption edge = 3.6074 eV) as previously reported (Vannini et al.,
2004).
In the structure of D101L Zn2+-HDAC8 (Dowling, Gantt et al., 2008), a
crystallographic dimer forms such that inhibitor binding in one monomer
precludes inhibitor binding in the symmetry related molecule (Figure 4.3.4),
resulting in 50% inhibitor occupancy in the active site of each monomer.
Accordingly, there is also electron density consistent with 50% occupancy of two
zinc-bound solvent molecules.  Similar inhibitor binding and metal coordination
interactions are observed in the structures of Co2+- and Fe2+-D101L HDAC8
(Figure 4.3.5), indicating that Zn2+, Co2+, and Fe2+ are each pentacoordinate with
square pyramidal geometry in the unliganded form of the enzyme.  In the Fe2+-
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Figure 4.3.1: Wild-type Co2+-HDAC8 complexed with M344
Anomalous difference map of the Co2+-wild-type human HDAC8 M344 complex
showing the presence of Co2+ (contoured at 3σ) in complex with the inhibitor
M344.  The enzyme packs as a crystallographic dimer with two molecules in the
asymmetric unit, which is similar to the Zn2+-HDAC8 M344 complex (Somoza et
al., 2004).  Monomer A and monomer B are shown in green and yellow,
respectively.
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Figure 4.3.2: D101L Co2+ and Fe2+-HDAC8 complexed with M344
Anomalous difference maps of the D101L HDAC8 variant complexed with the
inhibitor M344.  The Co2+ (left) and Fe2+ (right) forms of the enzyme are depicted
with anomalous difference maps for Co2+ (magenta) and Fe2+ (blue) contoured at
9σ and 4σ, respectively.  Leftover difference density is shown in red at 3σ.
Protein atoms are color coded as follows: carbon (yellow), oxygen (red), nitrogen
(blue).  Ions are colored as follows: cobalt (pink), iron (green).  Water molecules
are represented as red spheres.  The inhibitor and disordered glycerol molecule
(bound near the active site in the Co2+ structure) are colored similarly but with
carbon shown in green.
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Figure 4.3.3: Potassium anomalous signal
Anomalous difference maps (contoured at 3σ) of potassium bound in the two
monovalent cation binding sites within the Fe2+- D101L variant of HDAC8
complexed with M344.  A. Monovalent cation binding site adjacent to the active-
site.  Metal interacting atoms are shown as sticks and colored as follows: carbon
(yellow), oxygen (red), nitrogen (blue).  Potassium ions are shown as purple
spheres.  B. Distal monovalent cation binding site.  Atoms are colored similarly
as in A, and water molecules are represented as red spheres.
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Figure 4.3.4: D101L crystallographic dimer
Cartoon depiction of the Fe2+-D101L HDAC8 variant crystallographic dimer.
Monomer A and monomer B are shown in green and yellow, respectively.  Fe2+-
coordinating residues and D101 are shown as sticks.  Protein atoms are color
coded as follows: carbon (green or yellow), oxygen (red), nitrogen (blue).  Ions
are colored as follows: Fe2+ (gold), K+ (purple).  Inhibitor M344 atoms are colored
as follows: carbon (green or yellow), nitrogen (blue), oxygen (red).
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substituted enzyme, a small 3.5σ electron density peak is seen ~1.5 Å from the
Fe2+ center and is located close (~1.9 Å) to the metal-bound solvent molecules
(Figure 4.3.2).  This peak does not refine satisfactorily as a water molecule with
full or partial occupancy, so we have not built anything into this density in the
final model.
4.4 Discussion
Many hydrolytic enzymes are dependent on a transition metal ion for
catalytic activity; interestingly, such enzymes can exhibit a range of catalytic
activities when substituted with different transition metal ions.  It is instructive
to compare metal ion-activity relationships in three enzymes that share the
arginase fold: arginase, HDAC8, and acetylpolyamine amidohydrolase (APAH).
Maximal arginase activity results from the binding of two Mn2+ ions, and the
enzyme exhibits minimal activity levels with Ni2+ and Co2+; the KM value does not
significantly change with different metal ions (Carvajal et al., 1995).  APAH from
M. ramosa exhibits the general metal ion-activity trend Mn2+ > Co2+ > Zn2+ > Mg2+
> Cu2+ > Ca2+, but individual kinetic constants are not reported (Sakurada et al.,
1996).  Finally, the HDAC enzymes were initially thought to be zinc
metallohydrolases based on studies of the histone deacetylase-like protein from
A. aeolicus (Finnin et al., 1999), but HDAC8 exhibits the metal ion-activity
dependence Co2+ > Fe2+ > Zn2+ > Ni2+ > Mn2+ based on kcat/KM values (Gantt et al.,
2006).  While the kcat value measured for HDAC8 is not particularly sensitive to
the identity of the divalent metal ion, the KM values for Co2+-HDAC8 and Fe2+-
HDAC8 are 160 µM and 210 µM, respectively, in comparison with that of
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Figure 4.3.5: Co2+ and Fe2+ coordination polyhedron
Square-pyramidal Co2+ and Fe2+ coordination polyhedron in the liganded and
unliganded forms of HDAC8 D101L in complex with M344.  Atoms are color
coded as follows: carbon = yellow for Fe2+-stucture and grey for Co2+ structure,
nitrogen = blue, oxygen = red, Fe2+ = gold sphere, Co2+ = pink sphere, H2O =
pink spheres.  Metal coordination and hydrogen bond interactions are shown in
solid black and dotted red lines, respectively.
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1100 µM measured for Zn2+-HDAC8 (Gantt et al., 2006).  Additionally, the Ki
values measured for the hydroxamate inhibitors SAHA (Vorinostat) and M344
show a preference for Co2+ (Table 4.4).  These data implicate a substrate-metal ion
coordination interaction in the precatalytic Michaelis complex; moreover, as first
noted by Fierke’s group, these data suggest that HDAC8 may be a Fe2+-
metalloenzyme in vivo, given the greater biological abundance of this metal ion
(Gantt et al., 2006).
Metal ions in metalloenzymes can affect enzyme function by maintaining
the structure of the active site and providing coordination interactions for
substrate, transition state(s), and intermediate(s) that facilitate catalysis.  In the
active site of arginase, MnA2+ is weakly bound with square pyramidal geometry
by four protein ligands (Asp3His) and MnB2+ is bound with octahedral geometry
by four protein ligands (Asp3His); one aspartate, D124, serves as a bidentate
ligand (Kanyo et al., 1996).  Two aspartates and one hydroxide ion serve as
bridging ligands.  The MnB2+ site of arginase corresponds to the single metal
binding site of HDAC enzymes (Christianson, 2005, Dowling, Di Costanzo et al.,
2008).  In HDAC8 substituted with Zn2+, Co2+, and Fe2+, the divalent metal ion is
coordinated by three protein ligands (Asp2His) and two water molecules with
square pyramidal geometry.  Inspection of the HDAC8 active site suggests that
D234, which corresponds to D267 of arginase, cannot achieve a bidentate
coordination geometry to yield an octahedral coordination polyhedron.
Interestingly, one of the monovalent cation binding sites in HDAC8 includes the
backbone C=O groups of two of the three divalent metal ion coordination
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residues (H180 and D178) (Figure 4.3.3).  It appears that HDAC8 has evolved to
favor square planar metal coordination where the substrate C=O group displaces
one of the metal-bound water molecules and coordinates to an equatorial site in
the precatalytic Michaelis complex.
In contrast, the guanidinium group of L-arginine does not coordinate to
the metal ions in the precatalytic enzyme-substrate complex with arginase,
consistent with the lack of metal dependence on substrate binding affinity as
indicated by KM values (Carvajal et al., 1994, Carvajal et al., 1995).  Stability
constants for metals with ethylenediamine ligands are ranked Mn2+ < Fe2+ < Co2+,
Zn2+ < Ni2+, consistent with less favorable guanidino-Mn2+ interactions (Martell &
Smith, 1974-1989).  Similarly, acetylacetone binding constants rank in the order
Mn2+ < Zn2+ < Co2+ (Fe2+ data not currently available) (Martell & Smith, 1974-
1989).  Thus, it appears that in a system where a precatalytic substrate-metal
coordination interaction is not important, the metal ion with the smaller stability
constant is favored.  In contrast, in the HDAC enzymes where a precatalytic
C=O…metal coordination interaction is important, metal ions with larger
stability constants are favored.
Metal-hydroxide stability constants based on pKb values are ranked Zn2+ <
Fe2+ < Co2+ (Martell & Smith, 1974-1989) and may additionally correlate with the
ability of the metal ion in the HDAC8 active site to stabilize the negatively
charged tetrahedral intermediate and its flanking transition states.  Possibly, Co2+
and Fe2+ provide greater stabilization of the tetrahedral intermediate relative to
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Zn2+ in the HDAC8 active site, thereby accounting for the observed activity trend
(Gantt et al., 2006).
Interestingly, metal-hydroxide stability constants indicate that Mn2+
would be preferred for stabilizing the negative charge of a tetrahedral
intermediate.  This is difficult to reconcile with the fact that the tetrahedral
intermediate in the arginase reaction is neutral.  Perhaps Mn2+ ions are preferred
by arginase to ensure an adequate concentration of the metal-bridging hydroxide
ion that serves as the catalytic nucleophile.
In view of the significant stability constant of the Mn2+-hydroxide
complex, it is not clear why HDAC8 does not effectively utilize Mn2+ to facilitate
the stabilization of the tetrahedral intermediate and its flanking transition states
in catalysis: HDAC8 does bind Mn2+, but this metal ion does not confer
significant catalytic activity (Gantt et al., 2006).  This contrasts with the
acetylpolyamine deacetylase APAH, which exhibits maximal catalytic activity in
the presence of Mn2+ (Sakurada et al., 1996).  However, only general metal-
dependent activity has been characterized for APAH from M. ramosa, and
detailed kinetic parameters remain to be determined for metal-substituted forms
of the enzyme.
These data illuminate the differences in metal stoichiometry and
coordination polyhedra utilized by arginase and HDAC8.  While arginase binds
two Mn2+ ions for catalysis, only the MnB2+ site is conserved within the HDAC
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enzymes.  The MnA2+ site is replaced in the deacetylases by the catalytic histidines
H143 and H142.  Additionally, although data here indicate complete metal
incorporation of Mn2+ in HDAC8, little to no activity is observed in the presence
of Mn2+.  Similar to what is observed in Zn2+-D101L HDAC8, Co2+- and Fe2+-
D101L HDAC8 reveal a preference for a square pyramidal metal coordination
geometry as compared to the octahedral coordination of MnB2+ in arginase.
Analysis indicates a preference for “harder” transition metals in catalysis by
HDAC8.  Lastly, solution metal-content data indicates no incorporation of Fe3+,
consistent with the hypothesis of HDAC8 as a possible ferrous enzyme.  Upon
oxidation of the Fe2+ center and dissociation of Fe3+, other trace metals such as
Zn2+ can be incorporated to rescue catalytic activity, albeit at lower levels (Gantt
et al., 2006).
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 Chapter 5. Evolution of the arginase fold and functional
diversity
Much of this work is published in Dowling, D. P., Di Costanzo, L., Gennadios, H. A. &
Christianson, D. W. (2008). Cell. Mol. Life Sci. 65, 2039-2055.
5.1 Introduction
The occurrence of specific proteins within the three domains of life
(bacteria, archaea and eukarya) argues for their occurrence in the last common
ancestor (LCA; also known as the last universal common ancestor, LUCA, or
cenancestor) (Doolittle, 2000, Delaye et al., 2005).  Amino acid sequence identity is
generally the primary determinant of genes conserved within the LCA, and the
minimal gene content of the LCA has been proposed by Ouzounis and
colleagues (Ouzounis et al., 2006).  Interestingly, the minimal gene content of the
LCA includes enzymes belonging to the arginase superfamily, such as histone
deacetylase (HDAC) and agmatinase (Ouzounis et al., 2006, Ouzounis &
Kyrpides, 1994), so members of this superfamily likely herald the very
beginnings of life on the earth.
Sequence analysis alone, however, overlooks structural homologies
between topologically identical enzymes that lack significant sequence identity,
since sequence evolves more rapidly than structure in the divergent evolution of
proteins (Orengo & Thornton, 2005).  For example, HDAC and arginase share the
same α/β fold, yet these enzymes have experienced sufficient evolutionary drift
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that they exhibit insignificant amino acid sequence identity.  In another example,
it is likely that acetylpolyamine amidohydrolase enzymes will share the arginase
fold despite low sequence identity with arginase because they share ~20-25%
sequence identity with HDAC enzymes (Leipe & Landsman, 1997).  Ranea and
colleagues describe 140 ancestral superfamilies consisting of 104,087 domains
rooted in the LCA.  These proteins include the greater family of Rossmannoid
HAD-like hydrolases, which contain a signature parallel 5-stranded β-sheet
sandwiched between α-helices.  Interestingly, the metalloenzymes arginase,
HDAC, and acetylpolyamine amidohydrolase contain the possible remnants of a
Rossmannoid fold within a larger 8-stranded β-sheet, which may suggest an
evolutionary relationship with an ancestral HAD-like hydrolase (Ranea et al.,
2006, Burroughs et al., 2006, Leipe & Landsman, 1997).
Here, we summarize structure-function relationships for arginase and
compare these with other members of the arginase superfamily, including the
histone deacetylases and acetylpolyamine amidohydrolases.  The recruitment of
the arginase fold to serve other catalytic functions in various domains of life
suggests that this particular α/β fold is robustly stable and readily evolvable,
and the identification of the arginase superfamily in the LCA reflect the
importance of this enzyme fold’s ability to catalyze the hydrolysis of various
substrate molecules.  Additionally, cross reactivity of arginase and
acetylpolyamine amidohydrolase for acetyl-L-lysine is tested.
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5.2 Description of the Arginase Fold: Arginase, HDAC, and APAH
Arginase.  The first crystal structure of an arginase enzyme was that of rat
liver arginase (Kanyo et al., 1996), also known as arginase I, which revealed a
trimeric quaternary structure in which each monomer adopts an α/β fold
consisting of a central parallel 8 stranded β-sheet (strand order 21387456) flanked
on both sides by several α-helices (Figures 5.2.1 and 5.2.2).  The subsequently
determined crystal structures of trimeric human arginase I (Di Costanzo et al.,
2005) and human arginase II (Cama, Colleluori et al., 2003), as well as the
hexameric arginases from Bacillus caldovelox (Bewley et al., 1999) and Thermus
thermophilus (PDB accession codes 2EF4, 2EF5, and 2EIV), reveal identical tertiary
structures for individual monomers from each species.
Amino acid side chains that coordinate to the manganese ions in the
arginase active site (Figure 5.2.2) are located in loop segments immediately
adjacent to strands 8, 7, and 4 (indicated schematically in Figure 1.2.1).  The
binuclear cluster in the unliganded enzyme exhibits a MnA2+-MnB2+ separation of
~3.3 Å, in agreement with the separation measured in an electron paramagnetic
resonance spectroscopic study (Khangulov et al., 1995).  The crystal structure of
unliganded rat arginase I reveals that MnA2+ is coordinated by H101, D128, D124,
D232, and the metal-bridging hydroxide ion with square pyramidal geometry
(Kanyo et al., 1996).  However, the crystal structure of unliganded human
arginase I reveals an additional water molecule coordinated to MnA2+ which
completes a distorted octahedral metal coordination polyhedron (Di Costanzo,
Pique et al., 2007).  The MnB2+ ion is coordinated by H126, D234, D124, D232, and
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a hydroxide ion with distorted octahedral geometry in rat arginase I and human
arginase I.
Histone deacetylase.  The crystal structures of HDLP, HDAH, HDAC8, and
the catalytic domains of HDAC4 and HDAC7 all reveal the arginase topology: an
α/β fold consisting of a central parallel 8 stranded β-sheet (strand order
21387456) sandwiched between α-helices (Finnin et al., 1999, Min et al., 2007,
Somoza et al., 2004).  Closer inspection reveals that structural variations among
the enzymes are found in their α-helical content, as well as in the lengths of
corresponding β-strands [Figure 1.2.1].  That these HDAC enzymes adopt the
arginase fold despite sharing < 15% amino acid sequence identity indicates
substantial evolutionary divergence that has influenced metal specificity,
stoichiometry, and quaternary structure.
Acetylpolyamine amidohydrolase.  The enzyme class of acetylpolyamine
amidohydrolase (APAH) catalyzes the deacetylation of such substrates as acetyl-
putrescine, spermidine, and spermine.  These enzymes are represented in both
mammalian and bacterial species where they function in the polyamine
biosynthetic pathway to degrade acetylated polyamines (Marton & Pegg, 1995,
Seiler, 1987).  APAH is expected to adopt the arginase fold based on its low
sequence homology with class II HDAC enzymes (Figure 5.2.3) (Leipe &
Landsman, 1997), and recently the crystal structure of the enzyme from M.
ramosa confirms this to be true (Patrick Lombardi and David W. Christianson,
unpublished results).  The crystal structure confirms conservation of the arginase
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B.
Figure 5.2.1: Cartoon depiction of arginase enzyme
A. Ribbon-plot of the rat arginase trimer; the Mn2+-Mn2+ cluster in the active site
of each monomer is represented by a pair of spheres.  B. Stereoview of a single
rat arginase monomer with β-sheets and α-helices labeled.
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Figure 5.2.2: Conserved metal binding site
Metal binding sites of rat arginase I (PDB accession code 1RLA), HDLP (PDB
accession code 1C3P), HDAC8 (less the substrate molecule) (PDB accession code
2V5W), HDAC7 (PDB accession code 2NVR), HDAH (less the acetate molecule)
(PDB accession code 1ZZ0), and APAH (prior to refinement with Zn2+) (Patrick
Lombardi and David W. Christianson, unpublished results).  Conserved metal
ligands are shown with conserved colors in each enzyme active site.  Zn2+ and
Mn2+ ions appear as yellow and pink spheres, respectively; metal-bound solvent
molecules are shown as red spheres.  The D(A,V,L,F)H loop and an additional
aspartate residue ~100 residues upstream in sequence are conserved for Mn2+B
binding in arginase and Zn2+ binding in the HDAC and HDAC-like enzymes.
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Figure 5.2.3: Arginase/deacetylase secondary structure alignment
Amino acid sequences of human arginase I (Arg.I), human HDAC7, human
HDAC8, HDAH from Bordetella sp., and HDLP from A. aeolicus aligned by
secondary structure homology.  Sequences were first aligned using TOP3D and
then loop regions were manually adjusted with appropriate gaps to optimize the
alignment of each sequence with arginase and with its class partners (HDAC8
and HDLP are class I deacetylases, while HDAC7 and HDAH are class II
deacetylases).  The sequence of APAH was first aligned with HDAH by
optimization of amino acid sequence identity, and then by manual optimization
of predicted secondary structure with the observed secondary structure of
arginase.  Hydrophobic regions within areas of defined secondary structure and
catalytic residues are highlighted in grey.  The human arginase I structure is
shown with secondary structural elements labeled and color-coordinated.  The
predicted secondary structure of APAH is indicated by the same color scheme.
Additional β-strand and α-helix secondary structural elements observed in
HDAC enzymes but not observed in arginase are colored orange and navy blue,
respectively.  A blue asterisk indicates conserved catalytic residues, and a red
asterisk indicates conserved metal ligands.
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MnB2+ site at the edge of the central β-sheet near the C-terminal ends of strands 4
and 7 within APAH.  Specifically, the D(A,L,V,F)H + D motif (Figure 5.2.2) is
conserved for metal binding.
5.3 Divergent Evolution of the Arginase Fold
Arginase, HDAC, and APAH are metallohydrolases, and their overall
mechanisms are represented in Figure 5.3.1.  Arginase has evolved to favor
binding and turnover of a positively charged L-arginine, while both HDAC and
APAH favor catalyzing the hydrolysis of neutrally charged acetyl-L-lysine
residues (Christianson, 2005, Finnin et al., 1999, Sakurada et al., 1996).
Considering these enzymes share such similar metal binding sites within the
same protein fold, it is of interest to analyze divergences in metal ion preference
and quaternary structure.  Lastly, we will test for low levels of cross-reactivity
with different substrates.  Such cross-reactivity may support their evolutionary
relationships and provide information regarding their divergences in function.
Metal specificity.  The location of the metal binding site at the edge of the
central β-sheet near the C-terminal ends of strands 4 and 7 is conserved in
arginase, HDAC enzymes, HDAC-like enzymes, and APAHs.  Specifically, the
D(A,V,L,F)H + D motif [Figure 3] is conserved for metal binding in these
enzymes despite their significant evolutionary divergence.  However, arginase
binds 2 Mn2+ ions, whereas HDAC enzymes, HDAC-like enzymes, and APAHs
bind a single transition metal ion (typically Zn2+) as a consequence of substantial
amino acid sequence divergence, including the substitution of residues that
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coordinate to Mn2+A in arginase.  Interestingly, Gantt and colleagues found an
increase in activity of HDAC8 with Co2+ and Fe2+, while no activity was detected
with Mn2+.  Conflictingly, Sakurada and colleagues report highest activity for
APAH reconstituted with Mn2+; however, protein isolated from M. ramosa
showed a 1:1 ratio of Zn2+:APAH (Sakurada et al., 1996).
Zinc coordination polyhedra in proteins are usually observed with a
coordination number (CN) of 4 and a slightly distorted tetrahedral geometry,
with the possibility of an increased CN of 5 allowing for the electrostatic
stabilization of a charged intermediate, as seen in the HDAC mechanism.  The
Zn2+ ion is considered a “borderline” metal in hardness with an atomic radius of
0.74 Å compared to Mn2+, a “hard” metal with an atomic radius of 0.80 Å that
favors octahedral coordination (CN = 6) (Christianson, 1997, Christianson & Cox,
1999).  The protein ligands to the active site Zn2+ ion in HDAC and HDAC-like
enzymes, two aspartate residues and one histidine residue, are somewhat
atypical for mononuclear Zn2+ enzymes, which predominantly favor histidine
residues in catalytic sites (Gantt et al., 2006, Auld, 2001).  In HDAC8, two of the
Zn2+ ligands, D178 and H180, are located in a bend at the end of strand 4 and are
separated by an aliphatic residue (L179 in HDAC8; Figure 3).  A search of the
Protein Data Bank (pdb.org) using EMBL-EDI (http://www.ebi.ac.uk/msd-
srv/msdsite/getEntry) for Zn2+-containing proteins with a ligand set of Asp2His
yields 68 structures, of which only HDLP, HDAC8, HDAH, and HDAC7 contain
Asp2His ligand sets for mononuclear Zn2+ coordination in a catalytic site.  Other
pdb entries include: alkaline phosphatase (e.g. 1HQA (Zn2+3) and 2GA3 (Zn2+2-
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Figure 5.3.1: Arginase, HDAC, and APAH reactions
 Overall reactions catalyzed by: (a) arginase, (b) HDAC, and (c) APAH enzymes.
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Mg2+) clusters with AspHis2, Asp2HisSer, and Asp2(Glu)Thr ligand sets),
aminopeptidase (e.g. 1RTQ, Zn2+2 cluster with Asp2His and AspHisGlu ligand
sets), glutamate carboxypeptidase II (e.g. 2OR4, Zn2+2  cluster with Asp2His and
AspHisGlu ligand sets), epimerase (1TQX, mononuclear Zn2+ site with Asp2His2
ligand set), inorganic pyrophosphatase (1WPP, Zn2+2 cluster with Asp2His and
Asp3His ligand sets), isomerase (1DE6, Zn2+-Mn2+ cluster with Asp2HisGlu and
Asp2His ligand sets, respectively), lectin (2OX8, several mononuclear Zn2+ sites,
one with Asp2HisGlu ligand set), phosphodiesterase (1XN0, Zn2+-Mg2+ cluster
with Asp2His2 ligand set), pyrophosphatase-phosphodiesterase (2GSU, Zn2+2
cluster with Asp2HisThr and AspHis2 ligand sets), and a superantigen (1EU4,
Zn2+2 cluster with Asp2His and Asp ligand sets).
The same search performed on proteins containing Fe2+, Co2+, or Mn2+
yields 3, 1, and 55 hits, respectively.  The Fe2+ ions coordinated by Asp2His ligand
sets are all contained in binuclear metal clusters: human calcineurin heterodimer
(1AUI and 2P6B, Fe2+-Zn2+ cluster with Asp2His and AspHis2 ligand sets,
respectively) and inorganic pyrophosphatase mutant (2IW4, Fe2+2 cluster with
Asp2His and Asp3His ligand sets).  The single Co2+-containing protein is alkaline
phosphatase from E. coli (1Y6V, Co2+3 cluster with Asp2HisSer, AspHis2, and
AspGluThr ligand sets).  The 55 Mn2+-containing proteins consist primarily of
arginase and arginase-like protein structures, such as amidinohydrolase (1GQ6
and 1GQ7) and agmatinase (1WOG and 1WOI).  A few enzymes share the
Asp2His ligand set of the arginase MnB2+ binding site: binuclear manganese
binding bacteriophage λ Ser/Thr protein phosphatase (1G5B), mononuclear
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manganese binding galactosyltransferase LgtC from Neisseria meningitides
(1GA8); binuclear manganese binding inorganic pyrophosphatase (Family II)
(1K23 and 2ENX), binuclear manganese binding protein phosphatase-1 (1U32,
2BCD and 2IAE), and a putative diadenosine tetraphosphatase (2QJC).  Binuclear
lectin proteins (Asp2GluHis) also appear in this search.  Analysis of the above-
referenced proteins reveals that 1G5B, 1U32, 2BCD, and 2QJC share a similar
D(I,L)H + D motif for Mn2+ binding despite varying protein folds.
Quaternary structure.   Crystal structure data show that the arginase fold has
evolved to accommodate various quaternary structures, ranging from monomers
and dimers observed for HDAC and HDAC-like enzymes to trimers and
hexamers for arginases.  While all mammalian arginases are heterologous trimers
with C3 symmetry (rat arginase I (Kanyo et al., 1996), human arginase I (Di
Costanzo et al., 2005), human arginase II (Cama, Colleluori et al., 2003)), bacterial
arginases are hexameric and contain two C3 trimers that associate in face-to-face
fashion with overall D3 symmetry (Bewley et al., 1999).  An important feature of
trimer stabilization in rat arginase I is a ~20-residue “S”-shaped tail at the C-
terminus that accounts for 54% of intersubunit contacts (Figure 5.3.2).  However,
Mora and colleagues indicate that this tail is not necessary for trimerization of
human arginase I because its deletion does not disrupt trimerization (Mora et al.,
2000).  Additionally, conserved R255-E256 and R308-D204 intermolecular salt
links stabilize quaternary structure in rat arginase I and human arginase I (Di
Costanzo et al., 2005, Kanyo et al., 1996).  The E256Q, R308A, R308E, and R308K
variants of arginase I behave as monomers in solution.  All show lower thermal
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stability and R308 variants show kcat and catalytic efficiency values between 33-
41% and 13-17% of those reported for the wild-type enzyme.  However, Sabio
and colleagues report comparable kinetics to wild-type arginase for the E256Q
variant (Sabio et al., 2001, Lavulo et al., 2001).  In human arginase II, additional
salt links are observed: the side chain of R201 forms an intermonomer salt link
with E263, and the side chain of R205 forms an intermonomer hydrogen bond
with N209 (Cama, Colleluori et al., 2003).
HDAC8 functions as a monomer in solution (Vannini et al., 2004), while
HDAC1-3 enzymes function in multiprotein complexes that are involved in
transcriptional regulation (Ahringer, 2000, Wen et al., 2000).  These other class I
enzymes contain N-terminal segments important for oligomerization (Gregoretti
et al., 2004, Taplick et al., 2001, Yang et al., 2002), and recombinant mouse HDAC1
and recombinant human HDAC3 expressed in eukaryotic cells purify as active
enzymes only in multi-protein/multi-HDAC complexes (Li et al., 2004).
Specifically, recombinant HDAC3 is capable of forming dimers and trimers
(Yang et al., 2002), and SMRT and N-CoR both serve  as HDAC3 activating
cofactors (Guenther et al., 2001, Zhang, Kalkum et al., 2002, Guenther et al., 2002).
In contrast with the ~22-residue “S” shaped tail at the C-terminus of arginase
that facilitates trimerization, HDAC8 contains a ~40-residue C-terminal tail with
a loop-310-helix-loop segment that would destabilize arginase-like trimer
assembly (Figure 5.3.2).  Other class I HDAC enzymes including HDAC1 and
HDAC3 have additional C-terminal domains containing a nuclear localization
signal (NLS) (Escaffit et al., 2007, Taplick et al., 2001), and HDAC2 has a C-
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Figure 5.3.2: Oligomeric structures of arginase and HDAC8
Stereoview of the superposition of human arginase I (red) and HDAC8 (blue).
The two manganese ions are indicated as pink spheres, while the zinc ion is grey.
The HDAC8 C-terminal segment that would block intersubunit interactions
comparable to those observed in the arginase trimer is indicated in yellow.
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terminal basic amino acid stretch similar to that of HDAC1 (Taplick et al., 2001),
demonstrating that the C-terminal segments of proteins with arginase folds are
“evolvable” for stabilizing homomeric or heteromeric protein-protein
interactions.  The exception among the class I enzymes is HDAC8, which
contains an apparent NLS domain in its central catalytic domain (Hu et al., 2000).
The HDAC1-3 enzymes also contain N-terminal domains that govern
oligomerization (Figure 5.3.3), as well as interactions with other HDAC enzymes
and/or proteins such as Sin3 and RbAp48 (Gregoretti et al., 2004, Taplick et al.,
2001, Yang et al., 2002).
Additionally, various class IIa HDAC enzymes are known to interact with
other proteins, e.g. HDAC4 and HDAC5 interact with 14-3-3 proteins when
localized in the cytoplasm and HDAC3 when localized in the nucleus (Grozinger
& Schreiber, 2000, Martin et al., 2007), and HDAC4-5, HDAC7 and HDAC9
interact with C-terminal-binding protein (CtBP), heterochromatin P1 (HP1),
MEF2 transcription factor and many additional transcriptional corepressors,
kinases, and DNA-anchoring transcriptional factors (Martin et al., 2007). Similar
to various HDAC enzymes, APAH from M. ramosa is reported to exist as a
homodimer in solution (Fujishiro et al., 1988), although current structural work
indicates a majority of dimerization contacts come from within the catalytic
domain of the protein (Patrick Lombardi, unpublished work).  The requirement of
multiprotein complexes for recombinant HDAC and APAH deacetylase activity
is somewhat reminiscent of the fact that arginase evolved to increase enzyme
stability and activity through trimer formation; arginase is less stable as a
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Figure 5.3.3: Mammalian HDAC gene product diagrams
Diagram of gene products within the human HDAC family (Gregoretti et al.,
2004).  The catalytic domain is represented as orange, while the flanking protein
regions important for protein-protein interactions are colored white.  The blue
box over HDAC1-3 highlights the histone association domain (HAD), and the
box within the APAH catalytic domain signifies the L2-loop area, which contains
a large percentage of the dimerization contacts seen within the APAH
homodimer (Patrick Lombardi and David W. Christianson, unpublished results).
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monomer (Lavulo et al., 2001, Sabio et al., 2001), and except for data published by
Sabio and colleagues (Sabio et al., 2001), it also is less active as a monomer
(Lavulo et al., 2001).
5.4 Materials and Methods
Using protein kindly provided by Patrick Lombardi and Luigi Di
Costanzo in the Christianson Lab, activity measurements for APAH and human
arginase I were performed as previously described for the wild-type enzyme
(Gantt et al., 2006) using the commercially available Fluor de Lys kit (BIOMOL)
with Fluor de Lys substrate.  The KM and kcat of APAH with the Fluor de Lys
acetyl-L-lysine substrate were obtained using 50-1000 µM fluorogenic acetyl-L-
lysine substrate, 1.0 µM APAH, 25 mM Tris (pH 8.0), 137 mM NaCl, 2.7 mM KCl,
and 1 mM MgCl2.  Reactions were incubated at 25 °C for 10 minutes, quenched
with stop solution (Developer II (BIOMOL) and 50 µM inhibitor M344), and
tested for deacetylated product using a fluorescence plate reader (Fluoroskan II)
(ex = 355 nm, em = 460 nm).  Data were fit using the software GraphPad Prism.
Activity measurement for APAH with the the Fluor de Lys HDAC8
tetrapeptide substrate (ace-His-Arg-Lys(ac)-Lys(ac)-coumarin) were similarly
conducted with 1 µM enzyme, 50 µM substrate, 25 mM Tris (pH 8.0), 137 mM
NaCl, 2.7 mM KCl, and 1 mM MgCl2. Reactions were incubated for 25 minutes at
25 °C, and time points were taken, quenched with stop solution (Developer II
and 50 µM M344), and tested for deacetylated product.
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The arginase radioactive assay was used as previously reported (Di
Costanzo, Moulin et al., 2007) to test for hydrolysis of L-arginine by HDAC8.
Experiments were kindly performed by Monica Ilies in the Christianson Lab.
5.5 Results and Discussion
No deacetylase activity for an acetyl-L-lysine was detected for human
arginase I under the conditions tested.  Similarly, HDAC8 does not turnover L-
arginine (unpublished results).  This confirms a divergence in substrate binding,
where arginase utilizes a binuclear manganese cluster to bind and hydrolyze the
positively charged L-arginine residue (Kanyo et al., 1996) and HDAC8 utilizes a
mononuclear Co2+,Fe2+, or Zn2+ ion to bind and hydrolyze the neutrally charged
acetyl-L-lysine (Gantt et al., 2006).
Considering that both HDAC8 and APAH bind a neutrally charged
acetyl-amine moiety and catalyze its hydrolysis, some level of cross-reactivity is
expected.  Using the commercially available BIOMOL Fluor de Lys substrate,
which consists of an acetyl-L-lysine attached to a coumarin dye, APAH was
assayed for deacetylase activity.  Under similar conditions as used for HDAC8,
APAH was active against acetyl-L-lysine with a KM and kcat of 360 ± 60 µM and
0.18 ± 0.02 s-1, respectively (Figure 5.5).  Substrate affinity is comparable to the
average published acetylpolyamine KM value of approximately 220 µM
(Sakurada et al., 1996).  The enzyme kcat of the APAH protein construct expressed
by Patrick Lombardi has yet to be determined.
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Figure 5.5: APAH kinetics against acetyl-L-lysine
Activity measurements of APAH with A. BIOMOL Fluor de Lys substrate
(acetyl-L-lysine attached to a coumarin dye), and B. BIOMOL Fluor de Lys
HDAC8 substrate (ace-His-Arg-Lys(ac)-Lys(ac)-coumarin).  Wild type HDAC8 and
the catalytically dead H143A HDAC8 variant were used as positive and negative
controls for deacetylase activity.
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Interestingly, APAH shows greater activity for a free acetyl-L-lysine
substrate as compared to HDAC8.  This suggests that HDAC activity favors a
peptidic acetyl-L-lysine versus the free acetylated amino acid.  To confirm this,
APAH activity for a tetrapeptide HDAC8 substrate was tested (Figure 5.5).
HDAC8 and the inactive H143A HDAC8 variant were used as both positive and
negative controls for determining deacetylase activity.  No activity is seen for
APAH against the tetrapeptide, indicating that APAH favors catalysis of various
acetylated polyamines; adversely, HDAC activity shows optimal activity for an
acetyl-L-lysine within a peptide.
Chapters 2 and 3 discuss the importance of HDAC8 residue 101 within
the L2-loop in substrate binding.  Interestingly, the recent crystal structure of
APAH indicates the L2-loop within this structure is used primarily for
dimerization (Patrick Lombardi and David Christianson, unpublished results).  It
is tempting to suggest that HDAC enzymes have evolved a function for the L2-
loop in substrate binding while APAH has evolved to utilize the L2-loop for
oligomerization.
Further studies into the dependence of APAH quaternary structure on
activity, as well as the structures of larger peptide substrates bound to HDAC
enzymes and ligand complexes with APAH, would shed increased light on the
role of the L2-loop in these proteins.  Mutational analysis of L2-loop residues in
HDAC8 may also prove to be informative.
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 Chapter 6.  Expression, Kinetics, and Structural Studies of
Arginase from Plasmodium Falciparum
6.1 Introduction
Malaria, an infectious disease caused by a parasitic protozoan from the
phylum Apicomlexa (Preiser et al., 2000), is a serious health threat.  The parasite
is transmitted by the Anopheles mosquito.  While malaria is considered eradicated
in the United States, ten species of Anopheles mosquitoes are located within the
United States, presenting the possibility for the reintroduction of malaria
acquired in endemic countries.  Specifically, between 1957 and 2003 there were
63 outbreaks in the United States.  This contrasts with the 350-500 million cases of
malaria and over one million deaths, primarily of children within sub-Saharan
Africa, which are reported worldwide each year ((CDC), 2007, Greenwood &
Mutabingwa, 2002).  Four species of malaria specifically infect humans:
Plasmodium falciparum, vivax, malariae, and ovale, with Plasmodium falciparum being
the most lethal.  Methods of disease prevention and treatment include bed nets,
insecticides, and antimalarial drugs.  The parasite is capable of developing
resistance to drug therapy, and thus combinatorial drug therapies/cocktails are
necessary to prevent and possibly reverse the spread of drug resistance
(Winstanley et al., 2002, Kelly et al., 2009).
Invasion by a parasite such as malaria drastically alters host metabolic
functioning.  The parasite utilizes essential nutrients for its own survival at the
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expense of the host, introducing foreign waste products and toxins into the host’s
circulatory system (Planche et al., 2005).  The main pathogenesis of the disease
and its manifestations are due to the rapidly proliferating parasite cells, massive
erythrocyte lysis, and ischemia (Mackintosh et al., 2004).   Clinical manifestations
of malaria include hypoglycemia, lactic acidosis, hemolytic anemia,
hemoglobinuria, and hypoargininemia (Olszewski et al., 2009).
Metabolomic studies of Plasmodium falciparum during its 48 hr
intraerythrocytic life cycle reveal increased hydrolysis of host L-arginine to L-
ornithine and urea.  Malarial patients often suffer hypoargininemia, resulting in
decreased nitric oxide (NO) synthesis by nitric oxide synthase (NOS).  Host L-
arginine hydrolysis is the result of a secreted malarial arginase enzyme
(Olszewski et al., 2009).  The P. falciparum arginase gene has been identified based
on sequence identity to mammalian arginase enzymes, cloned and characterized
(Figure 6.1.2) (Müller et al., 2005, Olszewski et al., 2009).  It shares 28% and 27%
sequence identity with human arginase I and II (hAI and hAII), respectively.
Similar to mammalian arginase enzymes, P. falciparum arginase (PFA) is a
binuclear manganese metalloenzyme which exists as a functional trimer with
optimal activity at basic pH.  The arginase trimer is extremely thermostable, with
a reported Tm of 70 °C and 78 °C for rAI and hAI, respectively (Lavulo et al., 2001,
Sabio et al., 2001).  PFA exhibits a Tm of 57 °C, and its activity is reported to be
more dependent on quaternary structure and manganese concentration as
compared to hAI.  PFA displays optimal activity in vitro with 0.5 – 1 mM MnCl2,
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Figure 6.1.2: Arginase DNA alignment
DNA alignment of human arginase I (hAI), rat arginase I (rAI), hAII, rAII, and
Plasmodium arginase (PFA) using the software clustalW.  Conserved ligand
interacting residues are colored orange, and Mn2+ coordinating residues are
highlighted green.  The disordered N-terminal extension in hAII, rAII, and PFA
is colored magenta.
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as compared to 100 µM MnCl2 for hAI, and shows no detectable activity under
monomeric conditions (Müller et al., 2005, Wells et al., 2009).  This contrasts with
hAI which shows 13-17% activity as a monomer (Lavulo et al., 2001).  Kinetic
constants for PFA suggest that the malarial enzyme is less catalytically efficient
than the human arginase enzymes, with a kcat/KM of 7.7 X 103 M-1s-1 for PFA
versus 2.2 X 105 for hAI, respectively (Lavulo et al., 2001, Müller et al., 2005).
Substrate/inhibitor interacting residues are highly conserved between the
mammalian, bacterial, and malarial arginases.  In PFA, the only substitution is
T227S (Figures 6.1.2 and 6.1.3); yet, substrate affinity is significantly decreased as
compared to hAI.  Classical arginase inhibitors such as boronate and valine have
Ki values of 2.8 mM and 5.7 mM, respectively (Müller et al., 2005) as compared to
the hAI Ki value of 1.0 mM for borate in the presence of L-ornithine and the rAI
Ki value of 3.6 mM for valine (Baggio et al., 1997, Fuentes et al., 1994).  Such a
decrease in substrate affinity may be a result of structural and stability
differences in these enzymes as indicated by their varying Tm values.
PFA has a large 74-residue low complexity insert within its L2-loop
(Figures 1.3.1 and 6.1.2). Sequence alignment of the P. falciparum arginase gene
with that of P. vivax, P. yoelii, P. knowlesi, and P. berghei reveals this insert is as
large as 100 residues in P. vivax and small as 15 residues in P. berghei and shows
no significant conservation of sequence (Wells et al., 2009).  Such low complexity
regions (LCRs) comprise >90% of all proteins in the P. falciparum genome within
chromosomes 2 and 3, the first two sequenced P. falciparum chromosomes
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Figure 6.1.3: Arginase ligand-interacting residues
Diagram of Arginase I-ABH interactions.  Residues follow human arginase I
numbering.  Distances come from a.) 1.29 Å crystal structure of human arginase I
complexed with the boronic acid inhibitor 2(S)-amino-6-boronohexanoic acid
(ABH) (distances colored in purple, PDB accession code 2AEB (Di Costanzo et al.,
2005)), b.) 2.6 Å crystal structure of rat arginase I complexed with ABH (distances
colored in orange, PDB accession code 1T4P (Cama et al., 2004)), c.) 2.7 Å crystal
structure of PFA complexed with ABH (distances colored in green).  All ligand
interacting residues are conserved in the Plasmodium arginase except for a T135S
mutation.  Modified from: Di Costanzo, L., Sabio, G., Mora, A., Rodriguez, P. C.,
Ochoa, A. C., Centeno, F. & Christianson, D. W. (2005). Proc. Natl. Acad. Sci. U.
S. A. 102, 13058-13063.
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(Gardner et al., 1998, Pizzi & Frontali, 2001, Bowman et al., 1999).  For the 5,334 P.
falciparum genes, there are 37,100 LCRs (DePristo et al., 2006).  These low
complexity regions consist of either tandem-repeat insertions or homopolymer
runs (Pizzi & Frontali, 2001, Brocchieri, 2001).  Wells and colleagues also report a
second short insert (~12 residues in length) which is highly conserved among
malarial species.  It is located after the last β-strand and comprises loop L8
(Figure 1.3.1) (Wells et al., 2009).
Amino acid preference within the LCRs of P. falciparum correlates strongly
with genomic AT content.  The P. falciparum genome is 81% AT rich, and regions
with high AT content are primarily located within low complexity regions.  As
such, LCRs primarily consist of hydrophilic residues with a preference for
asparagine and lysine.  Low complexity regions are expected to exist primarily as
nonglobular external domains made up of hydrophilic and flexible amino acids,
and this seems to be the case expected for the L2-loop insertion for PFA (Gardner
et al., 1998).  Notably, these regions also contain the hydrophobic residues leucine
and isoleucine at comparable frequencies as compared to complex regions (Pizzi
& Frontali, 2001).
The research presented throughout this dissertation has studied the
importance of the L2-loop for inhibitor and substrate binding in HDAC8.
Acetylpolyamine amidohyrolase (APAH) adopts the same overall protein fold,
yet appears to utilize its L2-loop for protein dimerization (Patrick Lombardi and
David Christianson, unpublished results).  PFA also exemplifies how the L2-loop
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in the arginase enzyme is evolvable.  Despite these insertions, PFA still exists as
an active trimer.  The question remains as to if these are expendable, or if PFA
has evolved a function for both/either of these insertions.  Maintenance of such a
large insertion without a function seems rather improbable.  While LCR inserts
are thought to be external, nonglobular domains showing little effect on enzyme
function, examples including the dihydrofolate reductase-thymidylate synthase,
subtilisin-like protease-1, and S-adenosylmethionine decarboxylase/ornithine
decarboxylase of P. falciparum exemplify how these inserts can alter enzyme
activity and quaternary structure (Birkholtz et al., 2004, Jean et al., 2005,
Yuvaniyama et al., 2003).  Here, we have identified a suitable PFA clone for
kinetic and structural studies which shows comparable activity to the human
arginase enzymes.  Inhibition studies indicate PFA binds the boronic acid 2(S)-
amino-6-boronohexanoic acid (ABH) with µM affinity at physiological pH, and
deletion of the L2-loop insertion yields an active enzyme.  Lastly, structural
comparisons between the mammalian, bacterial, and plasmodium arginases
reveal differences which may help explain the observed decreases in Tm and
substrate affinity for the P. falciparum arginase.
6.2 Materials and Methods
6.2.1 Plasmodium falciparum arginase dN(1-21) and L2S constructs
Restriction enzymes and ligase were purchased from New England
Biosciences.  Taq Hifi Polymerase was purchased from Invitrogen.  All cell lines
were purchased from Stratagene.  The arginase gene was amplified from the C-
terminal His-tagged construct (PFA-C6H) obtained from the lab of Dr. Manuel
119
Llinás, Princeton University.  NheI and HindIII restriction sites were
incorporated so as to delete the first 21 amino acids (primer 1: GAG CGC TAG
CAA AAA CGT TTC CAT TAT TGG TTC TCC; primer 2: CTC AAG CTT TTA
CAC TAT ATC GTA TCC; restriction sites are underlined).  Digested PCR
product was ligated into PET28a (Novagen), utilizing the N-terminal his-tag and
thrombin cleavage site, and transformed into XL-1 Blue cells for DNA isolation
and sequencing.  For the L2-loop deletion construct (L2S), an AgeI restriction site
was incorporated into the dN(1-21) construct L2-loop, resulting in the deletion of
residues N84 to D157 (primer 1: CGG ACC GGT AAT ATA AGG AAT ATA AA;
primer 2: CGG ACC GGT TTT TTT TTC TTG TTT CAT; restriction sites are
underlined).  Digested product was purified using a Qiagen extraction kit and
transformed into XL-1 Blue cells for DNA isolation and sequencing.  Sequencing
was performed by the University of Pennsylvania DNA Sequencing Facility, and
the identified positive clone was then transformed into E. coli BL21-
CodonPlusTM(DE3)-RIL cells for expression as previously published (Müller et
al., 2005).
6.2.2 PFA-C6H and dN-PFA expression and purification
Briefly, transformed or streaked cells were grown on LB-agar
supplemented with 50 µg/mL kanamycin.  LB media supplemented with 50
µg/mL kanamycin was inoculated with a single colony and grown for 8 hours at
37 °C, 250 rpm.  This starter culture was then transferred to 250 mL LB media
supplemented with 50 µg/mL kanamycin and 34 µg/mL chloramphenicol and
grown for 12-16 hours.  The 250 mL cell growth was used to inoculate 5 L of M9
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minimal media supplemented with 5% cas-amino acids, 0.4% glucose, 2 mM
MgSO4, 0.1 mM CaCl2, 50 µg/mL kanamycin and 34 µg/mL chloramphenicol.
The temperature was dropped to 18 °C at an OD(600 nm) of 0.5 and allowed to
stabilize for 30 minutes.  Cells were induced with 0.4 mM IPTG for 22 hours.
Alternatively, protein expressed in LB media in the presence of 50 µg/mL
kanamycin, 10 µg/mL phenylmethylsulfonyl fluoride (PMSF) and 1 µg/mL of
tosyl-arginine methyl ester (TAME) at 37 °C with 1 mM IPTG was active and
crystallizes.
Cells were harvested by centrifugation at 6000g and resuspended in 50
mM Tris (pH 8.0), 500 mM NaCl, and 3 mM BME in the presence of protease
inhibitors (10 µg/mL PMSF and 1 µg/mL of TAME).  Cells were lysed by
sonication and centrifuged at 30,000g for 1 hr.  The supernatent was loaded onto
nickel-nitrilotriacetic acid resin and eluted by increasing imidazole
concentrations (10 mM, 50 mM, 200 mM).  Pulled protein fractions were dialyzed
into 50 mM Tris (pH 8.0), 200 mM NaCl, 1 mM MnCl2, and 1 mM TCEP and
subsequently further concentrated.  Protein was loaded onto the superdex 26/60
size exclusion column preequilibrated in dialysis buffer.  The trimer protein peak
was collected, concentrated down, and stored in aliquots at –80 °C or 4 °C.
6.2.3 Kinetic assay
dN-PFA, dN-PFA-L2S, and PFA-C6H were tested for activity.  Arginase
activity was determined using a colorimetric method (Archibald, 1945) with
slight modifications.  The reaction of urea with α-isonitroso propiophenone was
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measured at a wavelength of 550 nm using the Envision plate reader (Dr. Scott
Diamond laboratory, Institute of Medicine and Engineering, University of
Pennsylvania).  The reaction of L-arginine and arginase was carried out in 50 mM
Tris (pH 8.0), 0.5 mM TCEP, 1 mM MnCl2, 0.05-1 µM protein, and 1-200 mM L-
arginine for 5-10 minutes at 37 °C.  Assay mixture and protein were preincubated
at 37 °C for >1 minute before initiating the reaction.  Reactions at pH 8.5 were
stopped after 5 minutes.  The assay mixture (20 µL) was stopped with a sulfuric-
phosphoric acid/α-isonitroso propiophenone mixture (140 µL).  Reaction points
were developed in a thermocycler (90 °C, 1 hr), followed by incubation at room
temperature (21 °C, 15 min).  Inhibition studies were performed with 25 mM L-
arginine and reacted at 37 °C for 10 minutes in order to obtain significant
absorbance signals to plot IC50 data.  The Ki value for 2(S)-amino-6-
boronohexanoic acid (ABH) was calculated using the Cheng-Prusoff equation
(Cheng & Prusoff, 1973).  Data were fit accordingly using the software Graphpad
Prism (2008).
6.2.4 Crystallography
The inhibitor ABH was synthesized as previously described (Cama, Shin
et al., 2003).  Briefly, a 2 µL sitting drop of 5-10 mg/mL protein in 50 mM Tris
(pH 8.0), 200 mM NaCl, 1 mM MnCl2, 1 mM TCEP, and 5 mM of inhibitor (ABH)
was mixed with a drop of 1.4 M sodium/potassium phosphate (pH 8.2) and
equilibrated against a 500 µL reservoir of 40-50% MPD at room temperature.
Small crystals appeared overnight and grew to typical dimensions of 50 X 50 X 50
µm3.  Crystals were subsequently harvested and cryoprotected in 30% Jeffamine
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ED-2001 and 0.1 M HEPES (7.0) and flash frozen in liquid nitrogen.  Diffraction
data were measured on beamline X29 at the Brookhaven National Synchrotron
Light Source (NSLS, Brookhaven, NY).  Crystal and data collection statistics are
recorded in Table 6.1.
Data were indexed and merged using HKL2000 (Otwinowski & Minor,
1997).  Molecular replacement calculations were performed with PHASER
(McCoy et al., 2007) using the atomic coordinates of an inhibited form of human
arginase II less inhibitor and solvent atoms (PDB accession code 1PQ3) (Cama,
Colleluori et al., 2003) as a search probe for rotation and translation functions for
the PFA-ABH complex.  Iterative cycles of refinement and model building were
performed using PHENIX (Adams et al., 2002) and COOT (Emsley & Cowtan,
2004), respectively, in order to improve each structure as guided by Rfree values.
The N-terminal tag is completely disordered, and density begins at residue K22
of the PFA protein sequence.  Residues Q78 to K149 of the L2-loop insert are
disordered and excluded from the final model.  All refinement statistics are
recorded in Table 6.1.  A cis-linkage is found between residues G382 and D383.
This location is within the L8-loop insertion and adjacent to the unique H381,
which is observed to make novel interactions as described below.
123
Table 6.1: Data collection statistics
Structure dN-PFA-ABH complex
Cell Dimensions
a, b, c (Å) 112.8, 112.8, 229.2
α, β, γ (°) 90.0, 90.0, 120.0
Data Statistics
Resolution limits, Å 50 – 2.7
Space Group R32 (hexagonal)
Total/unique
reflections 29,223/15,643
Completeness (%)
(overall/outer shell) 100/100
Redundancy
(overall/outer shell) 5.2/5.2
Rmerge
a
(overall/outer shell) 0.144/0.493
I/σ(I)
(overall/outer shell) 10.5/2.6
Refinement
R/Rfreeb 0.196/0.227
No. of atoms
Protein atomsc, d 2,499
Water moleculesc 27
Ligand atomsc 12
Metal ionsc 2
Ramachandran (%)
Favored 86.7
Allowed 13.3
Generous 0
Forbidden 0
R.m.s. deviations
Bond lengths, Å 0.006
Bond angles, ˚ 1.1
Dihedrals, ˚ 19.4
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aRmerge = ∑I-〈I〉/∑I, where I is the observed intensity and 〈I〉 is the average
intensity calculated for replicate data.
bCrystallographic R factor, R = ∑(Fo -Fc)/∑Fo, for reflections contained in
the working set.  Free R factor, Rfree = ∑(Fo- Fc)/∑Fo, for reflections
contained in the test set excluded from refinement.  Fo and Fcare the
observed and calculated structure factor amplitudes, respectively.
cPer asymmetric unit.
dRefined residues 72 to 77 and 150 to 154 with occupancies of 0.5.
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6.3 Results and Discussion
Analysis of rat and human arginase crystal structures reveals the C-
terminus contains an approximate 20-residue S-shaped tail which mediates 54%
of intersubunit contacts.  Although this tail may not be vital for trimerization of
hAI (Mora et al., 2000), it is reasonable to question if the uncleavable tag at the C-
terminus of PFA might impede crystallization.  Also of interest, an alignment of
hAI, hAII, rAI, rAII, and PFA reveals that hAII, rAII, and PFA contain a ~21-
residue extension at the N-terminus as compared to hAI.  In the crystal structure
of hAI, visible electron density begins right before β-strand 1, indicating that the
disordered amino-terminal sequences in hAII and PFA may prohibit
crystallization.  This extension for hAII is in fact reported to be a mitochondrial
localization sequence.  Upon transport into the mitochondrion, tag cleavage
results in the mature form of the enzyme.  For crystal trials a truncation of hAII
was utilized in which the first 22 residues were deleted from the protein,
yielding the mature form of the enzyme (Cama, Colleluori et al., 2003).  For these
reasons, PFA was cloned into a pET28a vector and the first 21 residues were
deleted from its sequence, yielding the dN-PFA plasmid (Figure 6.3.3).
The activity of the dN-PFA construct was tested using published
conditions (Müller et al., 2005).  Catalytic efficiency (kcat/KM) increases as the pH
becomes more basic.  The kinetic values of different PFA constructs with L-
arginine were determined at pH 8.0 for comparison (Table 6.2).  Substrate
binding affinity varies between the N-terminally and C-terminally his-tagged
variants.  KM values for the N-terminally tagged enzyme correlate well with
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mammalian arginases (KM = 1.4 mM for rAI, pH 9.0 (Cavalli et al., 1994); 4.4 mM
for hAI, pH 8.7 (Carvajal et al., 1995); 0.55 mM for hAII, pH 9 (Colleluori et al.,
2001)).  This varies from the PFA-C6H construct (KM = 17 mM), as well as the
published KM value of 13 mM determined with a C-terminal strep-tag construct
by Müller and colleagues (Müller et al., 2005).  Data here raises the possibility
that a C-terminal tag is detrimental for activity.
The strongest mammalian arginase inhibitors known to date include
boronic acid derivatives (Christianson, 2005).  Specifically, the inhibitor 2(S)-
amino-6-boronohexanoic acid (ABH) inhibits hAI with a Kd of 5 nM (Di Costanzo
et al., 2005).  SPR was used to measure binding constants for ABH with PFA;
however, PFA is inactivated by the immobilization procedure and shows no
response to ligand.  Other methods of protein immobilization included a Ni-
NTA chip or immobilized antibody (PENTA, from Qiagen) on the CM5 chip to
bind his-tagged proteins.  Both methods were unsuccessful (data not shown);
therefore the inhibition constant of PFA with ABH was determined by means of
the reaction between urea and α-isonitroso propiophenone to generate a colored
solution as previously reported (Müller et al., 2005).  The Ki of PFA with ABH at
physiological pH is 11 ± 2 µM (Table 6.2).  This value is significantly larger than
the reported Kd of 5 nM for ABH against hAI (Di Costanzo et al., 2005).
To test the importance of the 75-residue L2-loop insertion in PFA, ~70
residues were deleted from the protein sequence.  A survey of the various
arginase crystal structures in the protein data bank supports the ability of this
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Figure 6.3.3: dN-PFA construct sequence alignment
Sequence alignment of wild type arginase from Plasmodium falciparum and the
dN-PFA clone generated here based on the sequence of human arginase II.  The
inserted N-terminal his-tag and thrombin cleavage site are colored magenta.
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Table 6.2: PFA kinetic parameters
Construct pH KM (mM) kcat (sec-1) Catalytic efficiency(kcat/KM) (M-1sec-1)
ABH Ki
(µM)
dN-PFA a
8.5 3.3 ± 0.6 392 ± 9 1.2 X 105 NDd
8.0 4.3 ± 0.6 300 ± 20 7.0 X 104 13 ± 2 µM
7.4 25 ± 2 77 ± 2 3.0 X 103 11 ± 2 µM
PFA-C6H
8.0 17 ± 2 40 ± 10 2.3 X 103 ND
PFA-Strep b
8.0 13b 100 b;; 24.8c 7.7 X 103; 1.9 X 103, c ND
dN-PFA L2S
8.0 4.6 ± 0.7 10 ± 10e ND ND
a dN-PFA signifies the N-terminally truncated form of PFA based off of sequence
alignment with human arginase II.  The N-terminal his-tag is not cleaved.
b Value and protein construct is taken from (Müller et al., 2005).
c Value is taken from (Wells et al., 2009).
d  ND signifies measurements not determined.
e The kcat value range is calculated using estimated protein concentrations due to
the low expression yields of the L2S construct.
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deletion clone to properly fold with the remaining L2-loop length.  The L2S clone
does not express well, but soluble protein expression is confirmed by Western
blotting analysis using an anti-his antibody (Figure 6.3.4).  Due to the lack of
protein expression, samples directly eluted from the affinity resin were dialyzed
into the final 1 mM MnCl2 containing buffer, concentrated, and tested for
activity.
The L2S clone has hydrolytic activity for L-arginine (Table 6.2).  Due to the
significant decrease in protein purity and expression, a proper protein
concentration is difficult to estimate.  A KM value of 4.6 ± 0.7 mM was determined
for the L2S construct, and an approximation of protein concentration yields a kcat
value of between 2-20 s -1.  The KM value is in accord with the dN-PFA construct,
confirming that the large L2-loop insertion does not greatly impact substrate
affinity.  Considering that the kcat approximation is on the order of lower activity
measurements reported for this enzyme, these data confirm that the deletion
does not drastically alter enzyme function.
PFA crystallizes as a trimer (Figures 6.3.5 and 6.3.6), confirming solution
studies that this enzyme behaves as a trimer in the presence of Mn2+ (Müller et al.,
2005).  The presence of a two-fold axis within the crystal generates a
crystallographic hexamer whose orientation resembles that previously observed
for the hexameric bacterial arginases from Thermus thermophilus and Bacillus
caldovelox (Bewley et al., 1999, Kumarevel et al., 2009).  However, less than 2%
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Figure 6.3.4: L2-loop deletion western PAGE analysis
X-ray film depiction of a western analysis of dN-PFA-L2S using a primary mouse
anti-His antibody and secondary IgG goat anti-mouse-HRP conjugate reacted
with horseradish peroxidase to generate chemiluminescence.  Lanes 1 and 2 are
positive control dN-PFA, while lanes 3-5 and 6-8 are two separate protein
expressions and purifications of the L2S construct.
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Figure 6.3.5: PFA-ABH complex crystals
Crystal hit of dN-PFA incubated with 5 mM ABH.  Condition came from
Hampton’s Index Screen (with 0.056 M sodium dihydrogen phosphate and 1.344
M dipotassium hydrogen phosphate) at room temperature.
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Figure 6.3.6: Initial crystal structure solution of the PFA-ABH complex
Cartoon depiction of the PFA trimer in complex with the inhibitor 2(S)-amino-6-
boronohexanoic acid (ABH).  The L2-loop insertion is disordered in the crystal
structure, while clear density is observed for the L8-loop insertion at the trimer
interface (colored in red).
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buried surface area between the symmetry related trimers confirms this hexamer
is not physiologically relevant (Jones & Thornton, 1995).  The trimer buries 3,893
Å2 of surface area per monomer, resulting in an approximate 15% buried surface
area within the trimer.
The PFA-ABH and hAI-ABH trimers superimpose with an r.m.s.
deviation of 1.21 Å for 816 Cα residues.  Minor deviations are seen in the β–sheet,
specifically for strands β1, β2, β3, and β6.  Main differences occur near the two
sequence insertions.  The approximately 70-residue L2-loop insertion is largely
disordered, and its first 6 residues (G72-K77) and last 5 residues (Y150-C154) are
modeled into visible density at half occupancy due to high B-factors.  The
location of these residues places this large insertion within a solvent pocket in the
crystal lattice located on the opposite end of the molecule from the trimer
interface.  This, along with kinetic data for the L2-loop deletion mutant, confirm
that the large L2-loop insertion does not impact catalysis or substrate binding.
Density is observed within the active site for two Mn2+ ions.  The
coordination geometry is very similar to that observed in the mammalian
arginases.  MnA2+ is coordinated by H193, D220, D216, and D323, and MnB2+ is
coordinated by H218, D216, D216, and D323.  One Oδ of D216 coordinates both
Mn2+ ions with a syn, anti-coordination, and Asp323 coordinates both Mn2+ ions
with syn, syn-bidentate geometry.  Density for the inhibitor ABH is clear, and it
binds as expected in comparison to the human arginase-ABH complexes
previously reported (Figure 6.3.7) (Cama et al., 2004, Di Costanzo et al., 2005).
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Several water molecules interact with the inhibitor and active site in the high
resolution structure of hAI complexed with ABH (Di Costanzo et al., 2005).  Here,
density for three ordered water molecules interacting with ABH is observed.
Two waters (A and B) interact with the NH3+ group of ABH.  Water A is within
hydrogen bonding distance to E277 and the backbone C=O of D272, and water B
is within hydrogen bonding distance to the carboxylate side-chain of D274, D272
and its backbone C=O group.  Water B is also close to residue His381 and is
discussed below.  Only one water molecule (water C) is observed within
hydrogen bonding distance to the carboxylate moiety of ABH.  Water C also
interacts with the hydroxyls of S229 and S231, as well as the backbone C=O
group of Asn231.
A great deal of work has indicated several salt bridges in the bacterial and
mammalian arginases to be important for stabilization of the trimer (Ash et al.,
1998, Lavulo et al., 2001, Sabio et al., 2001, García et al., 2009).  While several
interactions are conserved in the malarial form described here, there are
differences within the trimer interface which may account for the decrease in
thermal stability of PFA as compared to hAI.
At the center of the trimer interface, the human arginase I network
between D204A, E256A, and R255B is conserved as residues E295A, E347A, and
R346B in PFA(Figure 6.3.8).  The aspartate to glutamate mutation accompanies a
change in conformation for this residue.  In PFA, E295 is within hydrogen
bonding distance to R346 in an anti-orientation to the NεH group.
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Figure 6.3.7: Ligand environment in the PFA-ABH complex
2(S)-amino-6-boronohexanoic acid (ABH) inhibits PFA with a Ki of 11 µM
at pH 7.4 (determined by kinetic assay with 25 mM L-arginine).  The crystal
structure of PFA in complex with ABH reveals a binding mode similar to that of
mammalian arginase (Cama et al., 2004, Di Costanzo et al., 2005).  Intriguingly,
H381B from an adjacent monomer (colored green) extends from the L8-loop
insertion into the active site of monomer A.
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Figure 6.3.8: Intermonomer salt-bridge interactions
The arginase trimer contains several salt-bridges at the trimer interface.
The hAI subunit carbon atoms are colored in red, blue, and green; oxygen and
nitrogen atoms are colored red and blue, respectively.  The PFA trimer subunits
are colored similarly, except that carbon atoms are colored in grey.  The strong
R204A, E256B, and D204B hydrogen bonds in hAI are conserved in PFA by R346A,
E347B, and E295B.  The D to E mutation results in a conformational shift for
residue 295 in PFA.  The second salt bridge cluster depicted for hAI (R308A,
E262A, and D204B) is replaced in PFA by I410A, K353A, E295B, and F292A.
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A second hydrogen bonding network observed in mammalian arginase
and the arginase from T. thermophilus is not conserved within PFA.  This network
consists of D204A, E262A, and R308B in hAI (Figure 6.3.8) and is linked to the
above salt-link network through residue D204, which is within hydrogen
bonding distance to both R255B and R308B of an adjacent monomer.  In PFA,
these residues are mutated from the hAI sequence as follows: D204 -> E295, E262
-> K353, and R308 -> I410 (Figure 6.3.8).  Additionally, F292 is positioned within
the pocket resulting from these mutations.  Arginase from B. caldovelox does not
contain the corresponding R308 residue, and a free L-arginine is reported to bind
and make similar interactions as seen in the mammalian arginases (Bewley et al.,
1999).  The arginases from B. caldovelox and P. falciparum are currently the only
two arginase structures showing variance in this hydrogen-bonding network.
The 11-residue insert observed at the C-terminus of PFA is located
between a small 310-helix and the final α-helix.  The insert and final α-helix
combined make several interactions with the adjacent monomer, mediating
approximately 56% of intersubunit interactions and consist of various salt-
bridge, hydrogen bonding, and hydrophobic interactions which vary from the
mammalian arginases.
Within the insert II and helices G and H2, K340A protrudes into a pocket
within the adjacent monomer (Figure 6.3.9).  This pocket consists of Y345B, D377B,
D383B, K393B, K396B, and E400 B.  Of these residues, only Y345 is conserved as
Y254 in hAI.  The remaining residues are specific to the malarial enzyme.  K340 is
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Figure 6.3.9: PFA L8-loop intermonomer interactions
Unique intermonomer interaction seen in PFA within the L8-loop insert
and helices G and H2.  PFA monomers are colored green and yellow,
respectively.  The superimposed hAI structure is colored in grey. Dashed lines
are colored as red for hydrogen bond distances and cyan for salt-bridge
interaction at ~4 Å distances.  Oxygen and nitrogen atoms are colored red and
blue, respectively.  Captions are colored in black for hAI and green or yellow for
the respective PFA monomers.
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a valine residue in the mammalian arginases, and due to the variance in L8-loop
size, is rather solvent exposed.
The C-terminal residue of PFA, V411A, rests within a predominantly
hydrophobic pocket of the adjacent monomer (Figure 6.3.10).  This pocket
consists of I270B, I273B, Y288B, T290 B, K278B, and K282B.  This contrasts to hAI,
which contains a C-terminal extension as compared to the PFA sequence.  In hAI,
this pocket is replaced by a hydrogen-bonding network consisting of E309A,
H187B and Y197B.
A novel intermonomeric active site interaction is seen within the 11-
residue insert in PFA.  Density for H381 places this residue within the active site
of the adjacent monomer (Figures 6.3.6 and 6.3.7).  H381A is within hydrogen
bonding distance to residue D272B within the active site.  Intriguingly, H381A is
3.3 Å from the Cβ of the inhibitor molecule ABHB, interacting through van der
Waals interactions.  A water molecule interacts with the NH3+ group of the ABHB
molecule, D272B, D274B, and is also located within hydrogen bonding distance of
H381A.  Because H381A is oriented to properly hydrogen bond with the side chain
D272B, its conformation positions Cε1 of the imidazole ring 2.9 Å from water B.
The following two residues within the L8-loop insertion, G382 and D383, are
connected by a cis-linkage.  This may be important for allowing H381 to extend
towards the neighboring monomer.
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Figure 6.3.10:PFA C-terminal residue interactions
In PFA, the C-terminal V411 residue rests within a predominantly
hydrophobic pocket of the adjacent monomer.  This contrasts with hAI, which
contains several polar interactions in this portion of its S-shaped “tail” region.
PFA monomers are colored in grey and yellow, while hAI monomers are colored
in blue and green.  Oxygen and nitrogen atoms are colored red and blue,
respectively.
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An additional intramonomer interaction is seen between R404A, E401A
(both located within the final α-helix), and Q349A (from helix G).  These amino
acid contacts are located at the trimer interface.  They form a pocket which is
occupied by F292B from the adjacent monomer, possibly stabilized through
cation-π interactions with R404.  This contrasts with previously published results
from modeling of the PFA sequence based on mammalian arginase enzyme
structures (Wells et al., 2009).  Wells and colleagues proposed a novel
intermonomer interaction between E295 and R404 supported by mutational
analyses of these residues.  However, the crystal structure confirms E295
interacts with R346 and E347 as described above.  The location of these residues
may be important for trimer formation, but they do not interact as predicted by
Wells and colleagues.
Recently published kinetic studies of the P. falciparum arginase have
utilized recombinant expression of a C-terminally tagged construct, which shows
lower substrate affinities and enzyme turnover as compared to mammalian
arginase enzymes (Müller et al., 2005, Wells et al., 2009).  This work confirms that
a C-terminal tag affects substrate binding.  Both the substrate affinity and
enzyme turnover of the N-terminally tagged enzyme are more in line with
mammalian arginases.  Also, considering that the N-terminus of hAII prohibits
crystal growth (Cama, Colleluori et al., 2003), we have deleted the first 21
residues of PFA for crystallization attempts.  This construct crystallizes in
complex with the inhibitor ABH.  The structure has been solved and reveals
several differences within the trimer interface.  Additionally, a deletion mutant
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of the L2-loop LCR insert binds L-arginine with comparable affinity as is seen in
the dN-PFA enzyme, implicating this insert to be nonessential for protein
function.  Finally, dN-PFA has a Ki value of 11 ± 2 µM at physiological pH for the
boronic acid ABH.  Such moderate inhibition of PFA by ABH raises the
possibility of generating inhibitors specific towards the malarial enzyme so as
not to affect host arginase activity levels (Wells et al., 2009).  Perhaps H381 may
be exploited to favor binding within the P. falciparum arginase.  Further
mutational studies must probe the role of insert II for trimer formation and
enzyme function.
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